EurekaMag Full Text Articles Chapter 11,141

Obasaju, C.; Manola, J.; Hudes, G.R.; Khandekar, J.D.; Citrin, D.L.; Carbone, P.; Trump, D.L. 2001: Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885. American Journal of Clinical Oncology 24(2): 150-154

Fowler, J.M.; Blessing, J.A.; Burger, R.A.; Malfetano, J.H. 2002: Phase Ii evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study. Gynecologic Oncology 85(2): 311-314

Fracasso, P.M.; Blessing, J.A.; Wolf, J.; Rocereto, T.F.; Berek, J.S.; Waggoner, S. 2003: Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecologic Oncology 90(1): 177-180

Clark, J.I.; Hofmeister, C.; Choudhury, A.; Matz, G.; Collins, S.; Bastian, R.; Melian, E.; Emami, B.; Petruzzelli, G. 2001: Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 92(9): 2334-2340

Vaishampayan, U.; Flaherty, L.; Du, W.; Hussain, M. 2001: Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer 92(3): 519-523

Heath, E.I.; Burtness, B.A.; Heitmiller, R.F.; Salem, R.; Kleinberg, L.; Knisely, J.P.; Yang, S.C.; Talamini, M.A.; Kaufman, H.S.; Canto, M.I.; Topazian, M.; Wu, T.T.; Olukayode, K.; Forastiere, A.A. 2000: Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(4): 868-876

Bedikian, A.Y.; Papadopoulos, N.; Plager, C.; Eton, O.; Ring, S. 2003: Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Research 13(3): 303-306

Baidas, S.M.; Winer, E.P.; Fleming, G.F.; Harris, L.; Pluda, J.M.; Crawford, J.G.; Yamauchi, H.; Isaacs, C.; Hanfelt, J.; Tefft, M.; Flockhart, D.; Johnson, M.D.; Hawkins, M.J.; Lippman, M.E.; Hayes, D.F. 2000: Phase II evaluation of thalidomide in patients with metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(14): 2710-2717

Berlin, J.; Merrick, H.W.; Smith, T.J.; Lerner, H. 1999: Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). American Journal of Clinical Oncology 22(3): 291-293

Hoskins, P.; Eisenhauer, E.; Vergote, I.; Dubuc-Lissoir, J.; Fisher, B.; Grimshaw, R.; Oza, A.; Plante, M.; Stuart, G.; Vermorken, J. 2000: Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(24): 4038-4044

Diaz, G.J.; Squires, E.J. 2003: Phase II in vitro metabolism of 3-methylindole metabolites in porcine liver. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 33(5): 485-498

O'Brien, P.; Roos, D.; Pratt, G.; Liew, K.; Barton, M.; Poulsen, M.; Olver, I.; Trotter, G. 2000: Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(3): 519-526

Petruzelka, L. 2003: Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer. Anti-Cancer Drugs 14(Suppl): S7-S12

Breathnach, O.S.; Kasturi, V.; Kaye, F.; Herscher, L.; Georgiadis, M.S.; Edison, M.; Schuler, B.S.; Pizzella, P.; Steinberg, S.M.; O'Neil, K.; Johnson, B.E. 2002: Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer. American Journal of Clinical Oncology 25(3): 269-273

Girard, P.M.; Pegram, P.S.; Diquet, B.; Anderson, R.; Raffi, F.; Tubiana, R.; Sereni, D.; Boerner, D. 2000: Phase Ii placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. Journal of Acquired Immune Deficiency Syndromes 23(3): 227-235

Martinez, A.A.; Pataki, I.; Edmundson, G.; Sebastian, E.; Brabbins, D.; Gustafson, G. 2001: Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. International Journal of Radiation Oncology Biology Physics 49(1): 61-69

Murphy, G.P.; Tjoa, B.A.; Simmons, S.J.; Ragde, H.; Rogers, M.; Elgamal, A.; Kenny, G.M.; Troychak, M.J.; Salgaller, M.L.; Boynton, A.L. 1999: Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39(1): 54-59

Langer, C.J.; Ruffer, J.; Rhodes, H.; Paulus, R.; Murray, K.; Movsas, B.; Curran, W. 2001: Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics 51(1): 113-119

Chiarion Sileni, V.; Nortilli, R.; Aversa, S.M.; Paccagnella, A.; Medici, M.; Corti, L.; Favaretto, A.G.; Cetto, G.L.; Monfardini, S. 2001: Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Research 11(2): 189-196

Airoldi, M.; Pedani, F.; Succo, G.; Gabriele, A.M.; Ragona, R.; Marchionatti, S.; Bumma, C. 2001: Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91(3): 541-547

Chang, D.F.; Garcia, I.H.; Hunkeler, J.D.; Minas, T. 1999: Phase Ii results of an intraocular steroid delivery system for cataract surgery. Ophthalmology 106(6): 1172-1177

Brockstein, B.; Samuels, B.; Humerickhouse, R.; Arietta, R.; Fishkin, P.; Wade, J.; Sosman, J.; Vokes, E.E. 2001: Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Investigational New Drugs 19(3): 249-254

North American Glycine Antagonist, I.Neuroprotection (Gain) Investigators 2000: Phase II studies of the glycine antagonist GV150526 in acute stroke: The North American experience. Stroke 31(2): 358-365

Yeo, W.; Chan, K.K.; Mukwaya, G.; Ross, M.; Leung, W.T.; Ho, S.; Chan, A.T.; Johnson, P.J. 1999: Phase Ii studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. Cancer ChemoTherapy and Pharmacology 44(2): 124-130

Szumacher, E.; Wighton, A.; Franssen, E.; Chow, E.; Tsao, M.; Ackerman, I.; Andersson, L.; Kim, J.; Wojcicka, A.; Ung, Y.; Sixel, K.; Hayter, C. 2001: Phase II study assessing the effectiveness of Biafine cream as a prophylactic agent for radiation-induced acute skin toxicity to the breast in women undergoing radiotherapy with concomitant CMF chemotherapy. International Journal of Radiation Oncology Biology Physics 51(1): 81-86

Craighead, P.S.; Young, S. 1998: Phase II study assessing the feasibility of using elemental supplements to reduce acute enteritis in patients receiving radical pelvic radiotherapy. American Journal of Clinical Oncology 21(6): 573-578

Tefferi, A.; Levitt, R.; Li, C.Y.; Schroeder, G.; Tschetter, L.K.; Michalak, J.C.; Krook, J.E.; Witzig, T.E. 1999: Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia. American Journal of Clinical Oncology 22(5): 509-516

Lakhanpal, S.; Donehower, R.C.; Rowinsky, E.K. 2001: Phase II study of 4-Ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma. Investigational New Drugs 19(1): 69-76

Oza, A.M.; Elit, L.; Swenerton, K.; Faught, W.; Ghatage, P.; Carey, M.; Mcintosh, L.; Dorr, A.; Holmlund, J.T.; Eisenhauer, E. 2003: Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: An NCIC clinical trials group study (NCIC IND.116). Gynecologic Oncology 89(1): 129-133

Shields, A.F.; Philip, P.A.; LoRusso, P.M.; Ferris, A.M.; Zalupski, M.M. 1999: Phase Ii study of CI-958 in colorectal cancer. Cancer ChemoTherapy and Pharmacology 43(2): 162-164

Katsumata, N.; Watanabe, T.; Tominaga, T.; Ogawa, M.; Adachi, I.; Enomoto, K.; Kajiwara, T.; Kusama, M.; Yamada, Y.; Abe, O. 1999: Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology 43(6): 441-444

Kerbrat, P.; Dieras, V.; Pavlidis, N.; Ravaud, A.; Wanders, J.; Fumoleau, P. 2003: Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. European Journal of Cancer 39(3): 317-320

Nasta, S.Dwivedy.; Hoff, P.M.; George, C.S.; Neubauer, M.; Cohen, S.C.; Abbruzzese, J.; Winn, R.; Pazdur, R.M. 2003: Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer. American Journal of Clinical Oncology 26(2): 132-134

Rocereto, T.F.; Saul, H.M.; Aikins, J.A.; Paulson, J. 2000: Phase Ii study of mifepristone (RU486) in refractory ovarian cancer. Gynecologic Oncology 77(3): 429-432

Kawahara, M.; Furuse, K.; Segawa, Y.; Yoshimori, K.; Matsui, K.; Kudoh, S.; Hasegawa, K.; Niitani, H. 2001: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. British Journal of Cancer 85(7): 939-943

Dittrich, C.; Coudert, B.; Paz-Ares, L.; Caponigro, F.; Salzberg, M.; Gamucci, T.; Paoletti, X.; Hermans, C.; Lacombe, D.; Fumoleau, P. 2003: Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. European Journal of Cancer 39(3): 330-334

Caponigro, F.; Dittrich, C.; Sorensen, J.B.; Schellens, J.H.M.; Duffaud, F.; Ares, L. Paz; Lacombe, D.; De-Balincourt, C.; Fumoleau, P. 2002: Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. European Journal of Cancer 38(1): 70-74

Goncalves, A.; Camerlo, J.; Bun, H.; Gravis, G.; Genre, D.; Bertucci, F.; Resbeut, M.; Pech-Gourg, F.; Durand, A.; Maraninchi, D.; Viens, P. 2001: Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Research 21(2b): 1431-1437

Boku, N.; Ohtsu, A.; Shimada, Y.; Shirao, K.; Seki, S.; Saito, H.; Sakata, Y.; Hyodo, I. 1999: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(1): 319-323

Gravis, G.; Pech-Gourgh, F.; Viens, P.; Alzieu, C.; Camerlo, J.; Oziel-Taieb, S.; Jausseran, M.; Maraninchi, D. 1999: Phase Ii study of a combination of low-dose cisplatin with 13-cis-retinoic acid and interferon-alpha in patients with advanced head and neck squamous cell carcinoma. Anti-Cancer Drugs 10(4): 369-374

Beauchesne, P.; Soler, C.; Rusch, P.; Fotso, M.J.; Duthel, R.; Schmitt, T.; Brunon, J. 1999: Phase Ii study of a radiotherapy/etoposide combination for patients with newly malignant gliomas. Cancer ChemoTherapy and Pharmacology 44(3): 210-216

Beer, T.M.; Garzotto, M.; Eilers, K.M.; Lemmon, D. 2003: Phase Ii study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. Journal of Urology 169(5): 1738-1741

Levin, V.A.; Yung, W.K.A.; Bruner, J.; Kyritsis, A.; Leeds, N.; Gleason, M.J.; Hess, K.R.; Meyers, C.A.; Ictech, S.A.; Chang, E.; Maor, M.H. 2002: Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. International Journal of Radiation Oncology Biology Physics 53(1): 58-66

Cristofanilli, M.; Bryan, W.J.; Miller, L.L.; Chang, A.Y.; Gradishar, W.J.; Kufe, D.W.; Hortobagyi, G.N. 1998: Phase II study of adozelesin in untreated metastatic breast cancer. Anti-Cancer Drugs 9(9): 779-782

Ferrajoli, A.; O'Brien, S.M.; Cortes, J.E.; Giles, F.J.; Thomas, D.A.; Faderl, S.; Kurzrock, R.; Lerner, S.; Kontoyiannis, D.P.; Keating, M.J. 2003: Phase Ii study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98(4): 773-778

Culine, S.; Kramar, A.; Droz, J.P.; Théodore, C. 1999: Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. Journal of Urology 161(1): 173-175

Radin, A.I.; Kim, H.T.; Grant, B.W.; Bennett, J.M.; Kirkwood, J.M.; Stewart, J.A.; Hahn, R.G.; Dutcher, J.P.; Wiernik, P.H.; Oken, M.M. 2003: Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer 98(1): 100-109

Schedel, I.; Sutor, G.C.; Hunsmann, G.; Jurkiewicz, E. 1999: Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers. Vaccine 17(15-16): 1837-1845

Buckner, J.C.; Malkin, M.G.; Reed, E.; Cascino, T.L.; Reid, J.M.; Ames, M.M.; Tong, W.P.; Lim, S.; Figg, W.D. 1999: Phase Ii study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clinic Proceedings 74(2): 137-145

Okamoto, H.; Watanabe, K.; Nishiwaki, Y.; Mori, K.; Kurita, Y.; Hayashi, I.; Masutani, M.; Nakata, K.; Tsuchiya, S.; Isobe, H.; Saijo, N. 1999: Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(11): 3540-3545

Kollmannsberger, C.; Gerl, A.; Schleucher, N.; Beyer, J.; Kuczyk, M.; Rick, O.; Casper, J.; Sosada, M.; Rie, C.; Kanz, L.; Bokemeyer, C. 2000: Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anti-Cancer Drugs 11(7): 535-539

Yamada, Y.; Shirao, K.; Hyodo, I.; Arai, Y.; Denda, T.; Ambo, T.; Ohtsu, A. 2003: Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. Cancer ChemoTherapy and Pharmacology 52(2): 125-130

Varterasian, M.L.; Pemberton, P.A.; Hulburd, K.; Rodriguez, D.H.; Murgo, A.; Al-Katib, A.M. 2001: Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Investigational New Drugs 19(3): 245-247

Ron, I.G.; Vishne, T.H.; Kraminsky, N.; Bar-Am, A.; Inbar, M.J. 1999: Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer. American Journal of Clinical Oncology 22(1): 35-37

Verschraegen, C.F.; Kavanagh, J.J.; Loyer, E.; Bodurka-Bevers, D.; Kudelka, A.P.; Hu, W.; Vincent, M.; Nelson, T.; Levenback, C. 2001: Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer 92(9): 2327-2333

Van-Wijk, F.H.; Lhomme, C.[author, Reprint-Author]; Bolis, G.; Di-Palumbo, V. Scotto; Tumolo, S.; Nooij, M.; De-Oliveira, C.F.; Vermorken, J.B. 2003: Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. European Journal of Cancer 39(1): 78-85

Kucuk, O.; Pandya, K.J.; Skeel, R.T.; Hochster, H.; Abeloff, M.D. 1999: Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: An Eastern Cooperative Oncology Group study (PA 185). Breast Cancer Research and Treatment 57(2): 201-206

Içli, F.; Arican, A.; Cay, F.; Akbulut, H.; Dinçol, D.; Karaoğuz, H.; Demirkazik, A. 1999: Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil. Oncology 56(4): 297-300

Dreicer, R.; Manola, J.; Roth, B.J.; Cohen, M.B.; Hatfield, A.K.; Wilding, G. 2000: Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(5): 1058-1061

Pignata, S.; Silvestro, G.; Ferrari, E.; Selvaggi, L.; Perrone, F.; Maffeo, A.; Frezza, P.; Di Vagno, G.; Casella, G.; Ricchi, P.; Cormio, G.; Gallo, C.; Iodice, F.; Romeo, F.; Fiorentino, R.; Fortuna, G.; Tramontana, S. 1999: Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(3): 756-760

Tobinai, K.; Uike, N.; Saburi, Y.; Chou, T.; Etoh, T.; Masuda, M.; Kawano, F.; Matsuoka, M.; Taguchi, H.; Makino, T.; Asano, Y.; Tamura, K.; Ohashi, Y. 2003: Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. International Journal of Hematology 77(5): 512-517

Montillo, M.; Tedeschi, A.; O'Brien, S.; Di Raimondo, F.; Lerner, S.; Ferrajoli, A.; Morra, E.; Keating, M.J. 2003: Phase Ii study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97(1): 114-120

Bennett, J.M.; Young, M.S.; Liesveld, J.L.; Paietta, E.; Miller, K.B.; Lazarus, H.M.; Marsh, R.D.; Friedenberg, W.R.; Saba, H.T.; Hayes, F.A.; Dewald, G.W.; Hiddemann, W.; Rowe, J.M. 2001: Phase Ii study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study. American Journal of Hematology 66(1): 23-27

Mukai, M.; Morita, S. 1998: Phase II study of combination therapy of radiation and local administration of OK-432 for esophageal cancer. International Journal of Clinical Oncology 3(6): 370-373

Kumada, T.; Arai, Y.; Itoh, K.; Takayasu, Y.; Nakamura, K.; Ariyoshi, Y.; Tajima, K. 1999: Phase Ii study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer. Oncology 57(3): 216-223

Ratto, G.B.; Cafferata, M.A.; Scolaro, T.; Bruzzi, P.; Alloisio, A.; Costa, R.; Spessa, E.; Semino, C.; Melioli, G. 2000: Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. Journal of ImmunoTherapy 23(1): 161-167

Aihara, T.; Takatsuka, Y.; Itoh, K.; Sasaki, Y.; Katsumata, N.; Watanabe, T.; Noguchi, S.; Horikoshi, N.; Tabei, T.; Sonoo, H.; Hiraki, S.; Inaji, H. 2003: Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Oncology 64(2): 124-130

Pattaranutaporn, P.; Thirapakawong, C.; Chansilpa, Y.; Therasakvichya, S.; Ieumwananontachai, N.; Thephamongkhol, K. 2001: Phase Ii study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecologic Oncology 81(3): 404-407

Mattson, K.; Vansteenkiste, J.; Stupp, R.; Bargetzi, M.; Saarinen, A.; Jekunen, A.; Fillet, G.; Teixeira, M.; Gatzemeier, U.; Olivares, R.; Soussan-Lazard, K.; Bérille, J. 2000: Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. Anti-Cancer Drugs 11(1): 7-13

Okamoto, H.; Watanabe, K.; Segawa, Y.; Ichinose, Y.; Yokoyama, A.; Yoneda, S.; Niitani, H. 2000: Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer. International Journal of Clinical Oncology 5(5): 316-322

Yeo, W.; Mok, T.S.K.; Tse, K.K.; Kwan, W.H.; Lam, K.C.; Ho, W.M.; Chiu, S.K.W.; Chan, A.T.C.; Leung, T.W.T.; Mo, F.K.F.; Johnson, P.J. 2002: Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. Anti-Cancer Drugs 13(6): 655-662

Chen, Y.-M.; Perng, R.-P.; Lin, W.-C.; Wu, H.-W.; Tsai, C.-M.; Whang-Peng, J. 2002: Phase Ii study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. American Journal of Clinical Oncology 25(5): 509-512

Robinet, G.; Thomas, P.; Pérol, M.; Vergnenegre, A.; Lena, H.; Taytard, A.; Paillotin, D.; Bessa, E.H.; Schuller-Lebeau, M.P. 2000: Phase II study of docetaxel in inoperable advanced non small cell lung cancer. Bulletin du Cancer 87(3): 253-258

Lenzi, R.; Yalcin, S.; Evans, D.B.; Abbruzzese, J.L. 2002: Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Investigation 20(4): 464-472

Nabholtz, J.M.; Mackey, J.R.; Smylie, M.; Paterson, A.; Noël, D.R.; Al-Tweigeri, T.; Tonkin, K.; North, S.; Azli, N.; Riva, A. 2001: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(2): 314-321

Saad, E.D.; Kraut, E.H.; Hoff, P.M.; Moore, D.F.; Jones, D.; Pazdur, R.; Abbruzzese, J.L. 2002: Phase Ii study of dolastatin-10 as first-line treatment for advanced colorectal cancer. American Journal of Clinical Oncology 25(5): 451-453

Sonpavde, G.; Ansari, R.; Walker, P.; Sciortino, D.F.; Gabrys, G.T.; Murdock, A.; Gonin, R.; Einhorn, L.H. 2000: Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. American Journal of Clinical Oncology 23(1): 68-70

Laverdiere, C.; Kolb, E.A.; Supko, J.G.; Gorlick, R.; Meyers, P.A.; Maki, R.G.; Wexler, L.; Demetri, G.D.; Healey, J.H.; Huvos, A.G.; Goorin, A.M.; Bagatell, R.; Ruiz-Casado, A.; Guzman, C.; Jimeno, J.; Harmon, D. 2003: Phase Ii study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98(4): 832-840

Recchia, F.; Sica, G.; De Filippis, S.; Rosselli, M.; Pompili, P.L.; Rea, S. 2001: Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma. American Journal of Clinical Oncology 24(3): 232-236

Leaf, A.N.; Wolf, B.C.; Kirkwood, J.M.; Haselow, R.E. 2000: Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: An Eastern Cooperative Oncology Group Study (E1385). Medical Oncology 17(1): 47-51

Lynch, J.W.; Hei, D.L.; Braylan, R.C.; Rimzsa, L.M.; Staab, E.V.; Bewsher, C.J.; Mendenhall, N.P.; Hudson, J.K. 2002: Phase Ii study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma. American Journal of Clinical Oncology 25(4): 391-397

Aapro, M.S.; Van Wijk, F.H.; Van Der Burg, M.E.L.; Ten Bokkel Huinink, W.; Vergote, I.; Guastalla, J.P.; Rosso, R.; Kobierska, A.; Beex, L.V.A.; Namer, M.; Splinter, T.E.W.; Vermorken, J.B. 2003: Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group. European Journal of Cancer 39(8): 1141-1143

Nogué, M.; Cirera, L.; Arcusa, A.; Batiste-Alentorn, E.; Balil, A.; Font, A.; Perez-Gracia, J.L.; Carrasco, E.M.; Tusquets, I. 2002: Phase Ii study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anti-Cancer Drugs 13(8): 839-845

Philip, P.A.; Zalupski, M.M.; Vaitkevicius, V.K.; Arlauskas, P.; Chaplen, R.; Heilbrun, L.K.; Adsay, V.; Weaver, D.; Shields, A.F. 2001: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92(3): 569-577

Possinger, K.; Kaufmann, M.; Coleman, R.; Stuart, N.S.; Helsing, M.; Ohnmacht, U.; Arning, M. 1999: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anti-Cancer Drugs 10(2): 155-162

Brodowicz, T.; Wolfram, R.M.; Köstler, W.J.; Tomek, S.; Vaclavik, I.; Steger, G.G.; Teleky, B.; Függer, R.; Jakesz, R.; Zielinski, C.C. 2000: Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anti-Cancer Drugs 11(8): 623-628

Yang, T.S.; Lin, Y.C.; Chen, J.S.; Wang, H.M.; Wang, C.H. 2000: Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89(4): 750-756

D'agostino, G.; Amant, F.; Berteloot, P.; Scambia, G.; Vergote, I. 2003: Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecologic Oncology 88(3): 266-269

Larson, D.A.; Prados, M.; Lamborn, K.R.; Smith, V.; Sneed, P.K.; Chang, S.; Nicholas, K.M.; Wara, W.M.; Devriendt, D.; Kunwar, S.; Berger, M.; Mcdermott, M.W. 2002: Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. International Journal of Radiation Oncology Biology Physics 54(5): 1397-1404

Kim, W.S.; Kim, M.M.; Choi, H.J.; Yoon, S.S.; Lee, M.H.; Park, K.; Park, C.H.; Kang, W.K. 2001: Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Investigational New Drugs 19(1): 81-83

Wilailak, S.; Linasmita, V.; Srisupundit, S. 2001: Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer. Anti-Cancer Drugs 12(9): 719-724

Walters, R.S.; Holmes, F.A.; Valero, V.; Esparza-Guerra, L.; Hortobagyi, G.N. 1998: Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. American Journal of Clinical Oncology 21(4): 413-415

Lobo, F.; Frau, A.; Barnadas, A.; Méndez, M.; Lizón, J.; Provencio, M.; Albistur, J.J.; Martínez, P.; Sánchez, M.J.; Constenla, M.; Estévez, L.G. 1999: Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. Cancer ChemoTherapy and Pharmacology 44(Suppl): S5-S8

Mantovani, G.; Maccio, A.; Massa, E.; Mulas, C.; Mudu, M.C.; Massidda, S.; Massa, D.; Murgia, V.; Ferreli, L.; Succu, G.; Astara, G.; Proto, E.; Tore, G.; Mura, M.; Maxia, G. 2000: Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation. International Journal of Oncology 16(6): 1227-1233

Mantovani, G.; Macciò, A.; Massa, E.; Mulas, C.; Mudu, M.C.; Massidda, S.; Massa, D.; Murgia, V.; Ferreli, L.; Succu, G.; Astara, G.; Proto, E.; Tore, G.; Mura, M.; Maxia, G. 1999: Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical response and organ/function preservation. Oncology Reports 6(6): 1425-1430

Sugiyama, T.; Yakushiji, M.; Noda, K.; Ikeda, M.; Kudoh, R.; Yajima, A.; Tomoda, Y.; Terashima, Y.; Takeuchi, S.; Hiura, M.; Saji, F.; Takahashi, T.; Umesaki, N.; Sato, S.; Hatae, M.; Ohashi, Y. 2000: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58(1): 31-37

Ichiki, M.; Rikimaru, T.; Gohara, R.; Koga, T.; Kawayama, T.; Matunami, M.; Oshita, Y.; Kamimura, T.; Aizawa, H. 2003: Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer. Oncology 64(4): 306-311

Bamias, A.; Papamichael, D.; Syrigos, K.; Pavlidis, N. 2003: Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. Journal of ChemoTherapy 15(3): 275-281

Fírvida, J.L.; Irigoyen, A.; Vázquez-Estévez, S.; Díz, P.; Constenla, M.; Casal-Rubio, J.; Valladares-Ayerbes, M.; Castellanos, J.; Rodríguez, R.; Balcells, M. 2001: Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer 91(4): 704-711

DeVore, R.F.; Johnson, D.H.; Crawford, J.; Garst, J.; Dimery, I.W.; Eckardt, J.; Eckhardt, S.G.; Elfring, G.L.; Schaaf, L.J.; Hanover, C.K.; Miller, L.L. 1999: Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(9): 2710-2720

Booser, D.J.; Esteva, F.J.; Rivera, E.; Valero, V.; Esparza-Guerra, L.; Priebe, W.; Hortobagyi, G.N. 2002: Phase Ii study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer ChemoTherapy and Pharmacology 50(1): 6-8

Israel, V.P.; Garcia, A.A.; Roman, L.; Muderspach, L.; Burnett, A.; Jeffers, S.; Muggia, F.M. 2000: Phase Ii study of liposomal doxorubicin in advanced gynecologic cancers. Gynecologic Oncology 78(2): 143-147

Shields, A.F.; Lange, L.M.; Zalupski, M.M. 2001: Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer. American Journal of Clinical Oncology 24(1): 96-98

Gordon, A.N.; Granai, C.O.; Rose, P.G.; Hainsworth, J.; Lopez, A.; Weissman, C.; Rosales, R.; Sharpington, T. 2000: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(17): 3093-3100

Collichio, F.A.; Amamoo, M.Ahinee.; Fogleman, J.; Griggs, J.; Graham, M. 2002: Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer. American Journal of Clinical Oncology 25(2): 194-197

Quirt, I.; Bodurth, A.; Lohmann, R.; Rusthoven, J.; Belanger, K.; Young, V.; Wainman, N.; Stewar, W.; Eisenhauer, E. 2002: Phase II study of marimastat (BB-2516) in malignant melanoma: A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs 20(4): 431-437

Okuno, S.H.; Mailliard, J.A.; Suman, V.J.; Edmonson, J.H.; Creagan, E.T.; Nair, S.; Levitt, R.; Kugler, J.W. 2002: Phase Ii study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Cancer 94(8): 2224-2231

Edmonson, J.H.; Blessing, J.A.; Cosin, J.A.; Miller, D.Scott.; Cohn, D.E.; Rotmensch, J. 2002: Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: A Gynecologic Oncology Group Study. Gynecologic Oncology 85(3): 507-510

Wagenaar, H.C.; Pecorelli, S.; Mangioni, C.; van der Burg, M.E.; Rotmensz, N.; Anastasopoulou, A.; Zola, P.; Veenhof, C.H.; Lacave, A.J.; Neijt, J.P.; van Oosterom, A.T.; Einhorn, N.; Vermorken, J.B. 2001: Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. European Journal of Cancer 37(13): 1624-1628

Meropol, N.J.; Niedzwiecki, D.; Hollis, D.; Schilsky, R.L.; Mayer, R.J. 2001: Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer 91(7): 1256-1263

Fokkema, E.; Groen, H.J.; Bauer, J.; Uges, D.R.; Weil, C.; Smith, I.E. 1999: Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(12): 3822-3827

Kollmannsberger, C.; Brugger, W.; Hartmann, J.T.; Maurer, F.; Böhm, P.; Kanz, L.; Bokemeyer, C. 1999: Phase Ii study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anti-Cancer Drugs 10(5): 453-456

Hodi, F.Stephen.; Soiffer, R.J.; Clark, J.; Finkelstein, D.M.; Haluska, F.G. 2002: Phase II study of paclitaxel and carboplatin for malignant melanoma. American Journal of Clinical Oncology 25(3): 283-286

Gadgeel, S.M.; Shields, A.F.; Heilbrun, L.K.; Labadidi, S.; Zalupski, M.; Chaplen, R.; Philip, P.A. 2003: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. American Journal of Clinical Oncology 26(1): 37-41

Burch, P.A.; Richardson, R.L.; Cha, S.S.; Sargent, D.J.; Pitot, H.C.; Kaur, J.S.; Camoriano, J.K. 2000: Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. Journal of Urology 164(5): 1538-1542

Ceresoli, G.L.; Dell'oro, S.; Passoni, P.; Villa, E. 2000: Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma. Cancer 89(1): 89-96

Fracasso, P.M.; Brady, M.F.; Moore, D.H.; Walker, J.L.; Rose, P.G.; Letvak, L.; Grogan, T.M.; McGuire, W.P. 2001: Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(12): 2975-2982

Vaughn, D.J.; Manola, J.; Dreicer, R.; See, W.; Levitt, R.; Wilding, G. 2002: Phase Ii study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 95(5): 1022-1027

Shin, D.M.; Khuri, F.R.; Glisson, B.S.; Ginsberg, L.; Papadimitrakopoulou, V.M.; Clayman, G.; Lee, J.J.; Ang, K.K.; Lippman, S.M.; Hong, W.K. 2001: Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91(7): 1316-1323

Kosmas, C.; Tsavaris, N.B.; Malamos, N.A.; Vadiaka, M.; Koufos, C. 2001: Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(1): 119-126

Jóhannsson, J.; Specht, L.; Mejer, J.; Jensen, B.Anker. 2002: Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. International Journal of Radiation Oncology Biology Physics 54(5): 1466-1470

Vorobiof, D.A.; Rapoport, B.L.; Mahomed, R.; Karime, M. 2003: Phase Ii study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Research 13(2): 201-203

Shepherd, F.A.; Dancey, J.; Arnold, A.; Neville, A.; Rusthoven, J.; Johnson, R.D.; Fisher, B.; Eisenhauer, E. 2001: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92(3): 595-600

Chang, S.M.; Kuhn, J.G.; Robins, H.I.; Schold, S.C.; Spence, A.M.; Berger, M.S.; Mehta, M.P.; Bozik, M.E.; Pollack, I.; Schiff, D.; Gilbert, M.; Rankin, C.; Prados, M.D. 1999: Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(3): 984-990

Ajani, J.A.; Pazdur, R.; Dumas, P.; Fairweather, J. 1998: Phase II study of prolonged infusion of taxol in patients with metastatic colorectal carcinoma. Investigational New Drugs 16(2): 175-177

Kuebler, J.P.; King, G.W.; Triozzi, P.; Moore, T.; Kraut, E.H. 2001: Phase II study of pyrazoloacridine in metastatic renal cell carcinoma. Investigational New Drugs 19(4): 327-328

de la Torre, A.; Ramos, S.; Valcárcel, F.J.; Candal, A.; Regueiro, C.A.; Romero, J.; Magallón, R.; Salinas, J.; de las Heras, M.; Veiras, C.; Tisaire, J.L.; Aragón, G. 1999: Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer. International Journal of Radiation Oncology Biology Physics 45(3): 629-634

Blay, J.Y.; Judson, I.; Rodenhuis, S.; Hermans, C.; Smith, M.; Van-Glabbeke, M.; Verweij, J. 1999: Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anti Cancer Drugs 10(10): 873-877

Sato, A.; Kurihara, M.; Horikoshi, N.; Aiba, K.; Kikkawa, N.; Shirouzu, K.; Mitachi, Y.; Sakata, Y.; Wakui, A.; 'tomudex'-Cooperative-Study-Group 1999: Phase II study of raltitrexed (Tomudex(R)) in chemotherapy-pretreated patients with advanced colorectal cancer. Anti Cancer Drugs 10(8): 741-748

Shoji, T.; Tanaka, F.; Yanagihara, K.; Inui, K.; Wada, H. 2002: Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest 121(3): 821-824

Bex, A.; Otto, T.; Lümmen, G.; Rübben, H. 2002: Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer. Urologia Internationalis 69(4): 273-277

Vose, J.M.; Link, B.K.; Grossbard, M.L.; Czuczman, M.; Grillo-Lopez, A.; Gilman, P.; Lowe, A.; Kunkel, L.A.; Fisher, R.I. 2001: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(2): 389-397

Hejna, M.; Köstler, W.J.; Raderer, M.; Tomek, S.; Brodowicz, T.; Scheithauer, W.; Wiltschke, C.; Zielinski, C.C. 2000: Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. Anti-Cancer Drugs 11(8): 629-634

Propper, D.J.; Braybrooke, J.P.; Levitt, N.C.; O'Byrne, K.; Christodoulos, K.; Han, C.; Talbot, D.C.; Ganesan, T.S.; Harris, A.L. 2000: Phase Ii study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. British Journal of Cancer 82(11): 1759-1763

Khayat, D.; Chollet, P.; Antoine, E.C.; Monfardini, S.; Ambrosini, G.; Benhammouda, A.; Mazen, M.F.; Sorio, R.; Borg-Olivier, O.; Riva, A.; Ramazeilles, C.; Azli, N. 2001: Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(14): 3367-3375

Colburn, D.E.; Thomas, D.A.; Giles, F.J. 2003: Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia. Investigational New Drugs 21(1): 109-111

Mantovani, G.; Macciò, A.; Madeddu, C.; Mulas, C.; Massa, E.; Astara, G.; Ferreli, L.; Mudu, M.C.; Gramignano, G.; Murgia, V.; Lusso, M.R.; Mocci, M.; Cardia, A.; Mura, L. 2002: Phase Ii study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. Oncology Reports 9(4): 887-896

Kubicka, S.; Rudolph, K.L.; Tietze, M.K.; Lorenz, M.; Manns, M. 2001: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato-Gastroenterology 48(39): 783-789

Zaniboni, A.; Ardizzoni, A.; De Marinis, F.; Portalone, L.; Boni, C.; Meriggi, F.; Cafferata, M.Argenide.; Ariganello, O.; Torri, V.; Neumaier, C.Emilio.; Rosso, R. 2003: Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer. American Journal of Clinical Oncology 26(1): 84-88

Janinis, J.; Efstathiou, E.; Panopoulos, C.; Samantas, E.; Aravantinos, G.; Christodoulou, C.; Skarlos, D. 2000: Phase Ii study of temozolomide in patients with relapsing high grade glioma and poor performance status. Medical Oncology 17(2): 106-110

Tseng, J.E.; Glisson, B.S.; Khuri, F.R.; Shin, D.M.; Myers, J.N.; El-Naggar, A.K.; Roach, J.S.; Ginsberg, L.E.; Thall, P.F.; Wang, X.; Teddy, S.; Lawhorn, K.N.; Zentgraf, R.E.; Steinhaus, G.D.; Pluda, J.M.; Abbruzzese, J.L.; Hong, W.K.; Herbst, R.S. 2001: Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92(9): 2364-2373

Polee, M.B.; Kok, T.C.; Siersema, P.D.; Tilanus, H.W.; Splinter, T.A.; Stoter, G.; Van der Gaast, A. 2001: Phase Ii study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anti-Cancer Drugs 12(6): 513-517

Schwartz, G.K.; Ilson, D.; Saltz, L.; O'Reilly, E.; Tong, W.; Maslak, P.; Werner, J.; Perkins, P.; Stoltz, M.; Kelsen, D. 2001: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(7): 1985-1992

Propper, D.J.; Levitt, N.C.; O'Byrne, K.; Braybrooke, J.P.; Talbot, D.C.; Ganesan, T.S.; Thompson, C.H.; Rajagopalan, B.; Littlewood, T.J.; Dixon, R.M.; Harris, A.L. 2000: Phase Ii study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. British Journal of Cancer 82(11): 1776-1782

Lee, S-wook.; Choi, E.Kyung.; Lee, J.Shin.; Lee, S.Do.; Suh, C.; Kim, S-We.; Kim, W.Sung.; Ahn, S.Do.; Yi, B.Yong.; Kim, J.Hoon.; Noh, Y.Ju.; Kim, S.Ssan.; Koh, Y.; Kim, D.Soon.; Kim, W-Dong. 2003: Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics 56(4): 996-1004

Abitbol, A.; Abdel-Wahab, M.; Lewin, A.; Troner, M.; Rodrigues, M.Amelia.; Hamilton-Nelson, K.L.; Markoe, A. 2002: Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) in Stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol. International Journal of Radiation Oncology Biology Physics 53(4): 942-947

Fisher, B.; Won, M.; Macdonald, D.; Johnson, D.W.; Roa, W. 2002: Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of radiation therapy oncology group 9513. International Journal of Radiation Oncology Biology Physics 53(4): 980-986

Giles, F.J.; Feldman, E.J.; Roboz, G.J.; Larson, R.A.; Mamus, S.W.; Cortes, J.E.; Verstovsek, S.; Faderl, S.; Talpaz, M.; Beran, M.; Albitar, M.; O'brien, S.M.; Kantarjian, H.M. 2003: Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia Research 27(12): 1091-1096

Ueno, H.; Okada, S.; Okusaka, T.; Ikeda, M.; Kuriyama, H. 2002: Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncology 62(3): 223-227

Ibrahim, N.K.; Rahman, Z.; Valero, V.; Willey, J.; Theriault, R.L.; Buzdar, A.U.; Murray, J.L.; Bast, R.; Hortobagyi, G.N. 1999: Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86(7): 1251-1257

Steele, J.P.; Shamash, J.; Evans, M.T.; Gower, N.H.; Tischkowitz, M.D.; Rudd, R.M. 2000: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(23): 3912-3917

Sørensen, P.; Høyer, M.; Jakobsen, A.; Malmström, H.; Havsteen, H.; Bertelsen, K. 2001: Phase Ii study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecologic Oncology 81(1): 58-62

Robles, C.; Furst, A.J.; Sriratana, P.; Lai, S.; Chua, L.; Donnelly, E.; Solomon, J.; Sundaram, M.; Feun, L.; Savaraj, N. 2003: Phase Ii study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. Oncology Reports 10(4): 885-889

Berruti, A.; Sperone, P.; Bottini, A.; Gorzegno, G.; Lorusso, V.; Brunelli, A.; Botta, M.; Tampellini, M.; Donadio, M.; Mancarella, S.; De Lena, M.; Alquati, P.; Dogliotti, L. 2000: Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(19): 3370-3377

Smorenburg, C.H.; Bontenbal, M.; Seynaeve, C.; van Zuylen, C.; de Heus, G.; Verweij, J.; de Wit, R. 2001: Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Research and Treatment 66(1): 83-87

Mermershtain, W.; Lavrenkov, K.; Cohen, Y. 2000: Phase Ii study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. Journal of ChemoTherapy 12(2): 183-185

Cassinello, J.; López-Alvarez, P.; Martínez-Guisado, A.; Valladares, M.; Huidobro, G.; López, R.; Bohn, U.; Sevilla, I.; Ballesteros, P.; Jorge, M.; Pérez-Carrión, R.; Fernández, J.L.; Dorta, J. 2003: Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer. Medical Oncology 20(1): 37-43

Honecker, F.; Kollmannsberger, C.; Quietzsch, D.; Haag, C.; Schroeder, M.; Spott, C.; Hartmann, J.T.; Baronius, W.; Hempel, V.; Kanz, L.; Bokemeyer, C. 2002: Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anti-Cancer Drugs 13(5): 497-503

Yan-Zhao; Li-Liqing; Zhao-Wenhua; Et-Al 2001: Phase II study on domestic Topotecan in the treatment of SCLC and advanced ovarian cancer. Zhongguo Zhongliu Linchuang 28(7): 522-525

Lee, G.Young.; Kim, B-Seog.; Seo, Y.Tae.; Choi, S.Ho.; Kim, H.Jin.; Choi, D.Seog.; Ko, J.Young.; Yang, S.Hyun.; Byun, J.Hoon. 2003: Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma. Korean Journal of Internal Medicine 18(2): 104-108

Gedlicka, C.; Formanek, M.; Selzer, E.; Burian, M.; Kornfehl, J.; Fiebiger, W.; Cartellieri, M.; Marks, B.; Kornek, G.V. 2002: Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 63(2): 145-150

Preti, P.; Poggi, G.; Cuomo, A.M.; Robustelli della Cuna, F.S.; Zambelli, A.; Pavesi, L. 1999: Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC). Journal of ChemoTherapy 10(6): 492-495

Dylina, T.J. 1999: Phase II therapy for a chronic pain patient: a clinical report. Cranio: the Journal of Craniomandibular Practice 17(2): 126-131

Gordon, M.S.; Young, M.L.; Tallman, M.S.; Cripe, L.D.; Bennett, J.M.; Paietta, E.; Longo, W.; Gerad, H.; Mazza, J.; Rowe, J.M. 2000: Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: A study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leukemia Research 24(10): 871-875

Sekiguchi, H.; Akiyama, S.; Fujiwara, M.; Nakamura, H.; Kondo, K.; Kasai, Y.; Ito, K.; Sakamoto, J.; Takagi, H. 1999: Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus. Surgery Today 29(2): 97-101

Argiris, A.; Heald, P.; Kuzel, T.; Foss, F.M.; Distasio, S.; Cooper, D.L.; Arbuck, S.; Murren, J.R. 2001: Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. Investigational New Drugs 19(4): 321-326

Ellerhorst, J.A.; Bedikian, A.Y.; Smith, T.M.; Papadopoulos, N.E.; Plager, C.; Eton, O. 2002: Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anti-Cancer Drugs 13(2): 169-172

Hoffman, M.A.; Blessing, J.A.; Morgan, M. 2000: Phase Ii trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. a Gynecologic Oncology Group Study. Gynecologic Oncology 79(3): 463-465

Dreicer, R.; See, W.A.; Klein, E.A. 2001: Phase II trial of GM-CSF in advanced prostate cancer. Investigational New Drugs 19(3): 261-265

Markovic, S.N.; Suman, V.J.; Vukov, A.M.; Fitch, T.R.; Hillman, D.W.; Adjei, A.A.; Alberts, S.R.; Kaur, J.S.; Braich, T.A.; Leitch, J.M.; Creagan, E.T. 2002: Phase II trial of KW2189 in patients with advanced malignant melanoma. American Journal of Clinical Oncology 25(3): 308-312

Giaccone, G.; O'brien, M.E.R.; Byrne, M.J.; Bard, A.; Kaukel, E.; Smit, B. 2002: Phase II trial of ZD0473 as second-line therapy in mesothelioma. European Journal of Cancer 38(Suppl 8): S19-S24

Ardavanis, A.; Extra, J.M.; Espié, M.; Cuvier, C.; Marty, M. 1998: Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer. In Vivo 12(5): 559-562

Zang, D.Y.; Lee, K.H.; Lee, J.S.; Lee, J.H.; Kim, W.K.; Kim, S.H.; Kim, W.D.; Kim, D.S.; Kim, J.H.; Kim, B.S.; Cho, Y.B.; Kim, D.K.; Kim, K.H. 1999: Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer. American Journal of Clinical Oncology 22(5): 495-498

Pivot, X.; Cals, L.; Cupissol, D.; Guardiola, E.; Tchiknavorian, X.; Guerrier, P.; Merad, L.; Wendling, J.L.; Barnouin, L.; Savary, J.; Thyss, A.; Schneider, M. 2001: Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck. Oncology 60(1): 66-71

Palermo, J.A.; Richards, F.; Lohman, K.K.; Lovelace, J.V.; Atkinson, J.; Case, L.D.; White, D.R.; Blackstock, A.W. 2000: Phase II trial of adjuvant radiation and intraperitoneal 5-fluorouracil for locally advanced colon cancer: Results with 10-year follow-up. International Journal of Radiation Oncology Biology Physics 47(3): 725-733

Lad, T.; Rosen, F.; Sciortino, D.; Brockstein, B.; Keubler, J.P.; Arietta, R.; Vokes, E. 2000: Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer. Investigational New Drugs 18(3): 261-263

Taylor, S.A.; Rankin, C.; Townsend, J.J.; Craig, J.B.; Vance, R.B.; Solank, D.L.; Brown, T.D.; Jaeckle, K. 2002: Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group study. Investigational New Drugs 20(1): 113-115

Motzer, R.J.; Amato, R.; Todd, M.; Hwu, W-J.Poo.; Cohen, R.; Baselga, J.; Muss, H.; Cooper, M.; Yu, R.; Ginsberg, M.S.; Needle, M. 2003: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Investigational New Drugs 21(1): 99-101

Vuky, J.; Yu, R.; Schwartz, L.; Motzer, R.J. 2002: Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investigational New Drugs 20(3): 327-330

Kucuk, O.; Fisher, E.; Moinpour, C.M.; Coleman, D.; Hussain, M.H.; Sartor, A.O.; Chatta, G.S.; Lowe, B.A.; Eisenberger, M.A.; Crawford, E.D. 2001: Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group study (SWOG 9235). Urology 58(1): 53-58

Margolin, K.A.; Liu, P.Y.; Unger, J.M.; Fletcher, W.S.; Flaherty, L.E.; Urba, W.J.; Hersh, E.M.; Hutchins, L.E.; Sosman, J.A.; Smith, J.W.; Weiss, G.R.; Sondak, V.K. 1999: Phase Ii trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. Journal of Cancer Research and Clinical Oncology 125(5): 292-296

Taamma, A.; Fandi, A.; Azli, N.; Wibault, P.; Chouaki, N.; Hasbini, A.; Couteau, C.; Armand, J.P.; Cvitkovic, E. 1999: Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 86(7): 1101-1108

Pohlmann, P.; DiLeone, L.P.; Cancella, A.I.; Caldas, A.P.F.; Dal Lago, L.; Campos, O.; Monego, E.; Rivoire, W.; Schwartsmann, G. 2002: Phase Ii trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. American Journal of Clinical Oncology 25(5): 496-501

Riva, C.; Lavieille, J.P.; Schmerber, S.; Cuisnie, O.; Reyt, E. 2000: Phase Ii trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. International Journal of Oncology 17(3): 543-549

Kucuk, O.; Shevrin, D.H.; Pandya, K.J.; Bonomi, P.D. 2000: Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). American Journal of Clinical Oncology 23(4): 371-375

Morris, T.C.; Ranaghan, L.; Morrison, J. 2001: Phase Ii trial of clarithromycin and pamidronate therapy in myeloma. Medical Oncology 18(1): 79-84

Morgan, R.J.; Braly, P.; Leong, L.; Shibata, S.; Margolin, K.; Somlo, G.; McNamara, M.; Longmate, J.; Schinke, S.; Raschko, J.; Nagasawa, S.; Kogut, N.; Najera, L.; Johnson, D.; Doroshow, J.H. 2000: Phase Ii trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. Gynecologic Oncology 77(3): 433-438

Jefford, M.; Toner, G.C.; Smith, J.G.; Ngan, S.Y.K.; Rischin, D.; Guiney, M.J. 2002: Phase Ii trial of continuous infusion carboplatin, 5-fluorouracil, and radiotherapy for localized cancer of the esophagus. American Journal of Clinical Oncology 25(3): 277-282

Daliani, D.D.; Assikis, V.; Tu, S.-M.; Papandreou, C.N.; Pagliaro, L.C.; Holtkamp, T.; Wang, X.; Thall, P.F.; Logothetis, C.J. 2003: Phase Ii trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 97(3): 561-567

Atagi, S.; Kawahara, M.; Ogawara, M.; Matsui, K.; Masuda, N.; Kudoh, S.; Negoro, S.; Furuse, K. 2000: Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology 30(2): 59-64

Covens, A.; Brunetto, V.L.; Markman, M.; Orr, J.W.; Lentz, S.S.; Benda, J. 2003: Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology 89(3): 470-474

Miller, V.A.; Krug, L.M.; Ng, K.K.; Pizzo, B.; Perez, W.; Heelan, R.T.; Kris, M.G. 2000: Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(6): 1346-1350

Heath, E.I.; Urba, S.; Marshall, J.; Piantadosi, S.; Forastiere, A.A. 2002: Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investigational New Drugs 20(1): 95-99

Pazdur, R.; Royce, M.E.; Rodriguez, G.I.; Rinaldi, D.A.; Patt, Y.Z.; Hoff, P.M.; Burris, H.A. 1999: Phase II trial of docetaxel for cholangiocarcinoma. American Journal of Clinical Oncology 22(1): 78-81

Goh, B.C.; Lehnert, M.; Lim, H.L.; Ng, A.W.; Chan, C.C.; Kong, H.L.; Lee, S.C.; Wee, J.; Chua, E.T.; Wong, J.E. 2000: Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer. Acta Oncologica 39(2): 225-229

Colevas, A.D.; Norris, C.M.; Tishler, R.B.; Fried, M.P.; Gomolin, H.I.; Amrein, P.; Nixon, A.; Lamb, C.; Costello, R.; Barton, J.; Read, R.; Adak, S.; Posner, M.R. 1999: Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(11): 3503-3511

Ellerhorst, J.A.; Bedikian, A.; Ring, S.; Buzaid, A.C.; Eton, O.; Legha, S.S. 1999: Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncology Reports 6(5): 1097-1099

Sparano, J.A.; O'Neill, A.; Schaefer, P.L.; Falkson, C.I.; Wood, W.C. 2000: Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(12): 2369-2377

Sparano, J.A.; Hu, P.; Rao, R.M.; Falkson, C.I.; Wolff, A.C.; Wood, W.C. 1999: Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(12): 3828-3834

Meyers, F., J.; Lew, D.; Lara, P., N.,. Jr.;; Williamson, S.; Marshall, E.; Balcerzak, S., P.; Rivkin, S., E.; Samlowski, W.; Crawford, E.D.vid 1998: Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124). Investigational New Drugs 16(4): 347-351

Jeen, Y.T.; Yoon, S.Y.; Shin, S.W.; Kim, B.S.; Mok, Y.J.; Kim, C.S.; Hyun, J.H.; Kim, J.S.; Kim, Y.H. 2001: Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 91(12): 2288-2293

Bedikian, A.Y.; Legha, S.S.; Eton, O.; Buzaid, A.C.; Papadopoulos, N.; Plager, C.; McIntyre, S.; Viallet, J. 1999: Phase Ii trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anti-Cancer Drugs 10(8): 735-739

Dreicer, R.; Manola, J.; Schneider, D.J.; Schwerkoske, J.F.; George, C.S.; Roth, B.J.; Wilding, G. 2003: Phase Ii trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 97(11): 2743-2747

Schmid, P.; Akrivakis, K.; Flath, B.; Grosse, Y.; Sezer, O.; Mergenthaler, H.G.; Possinger, K. 1999: Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anti-Cancer Drugs 10(7): 625-631

Okuno, S.; Edmonson, J.; Mahoney, M.; Buckner, J.C.; Frytak, S.; Galanis, E. 2002: Phase Ii trial of gemcitabine in advanced sarcomas. Cancer 94(12): 3225-3229

Okuno, S.; Ryan, L.M.; Edmonson, J.H.; Priebat, D.A.; Blum, R.H. 2003: Phase Ii trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97(8): 1969-1973

Späth-Schwalbe, E.; Genvresse, I.; Koschuth, A.; Dietzmann, A.; Grunewald, R.; Possinger, K. 2000: Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anti-Cancer Drugs 11(5): 325-329

Einhorn, L.H.; Stender, M.J.; Williams, S.D. 1999: Phase II trial of gemcitabine in refractory germ cell tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(2): 509-511

Kaufman, D.; Raghavan, D.; Carducci, M.; Levine, E.G.; Murphy, B.; Aisner, J.; Kuzel, T.; Nicol, S.; Oh, W.; Stadler, W. 2000: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(9): 1921-1927

Gertz, M.A.; Lacy, M.Q.; Lust, J.A.; Greipp, P.R.; Witzig, T.E.; Kyle, R.A. 1999: Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. American Journal of Hematology 61(2): 115-119

Gertz, M.A.; Lacy, M.Q.; Lust, J.A.; Greipp, P.R.; Witzig, T.E.; Kyle, R.A. 1999: Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Medical Oncology 16(2): 104-109

Mehta, M.P.; Tannehill, S.P.; Adak, S.; Martin, L.; Petereit, D.G.; Wagner, H.; Fowler, J.F.; Johnson, D. 1998: Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 16(11): 3518-3523

Salman, H.; Perez, A.; Sparano, J.A.; Ratech, H.; Negassa, A.; Hopkins, U.; Villani, G.; Fuks, J.; Wiernik, P.H. 2003: Phase Ii trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma. American Journal of Clinical Oncology 26(4): 338-343

Chiarion-Sileni, V.; Bononi, A.; Fornasa, C.Veller.; Soraru, M.; Alaibac, M.; Ferrazzi, E.; Redelotti, R.; Peserico, A.; Monfardini, S.; Salvagno, L. 2002: Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 95(3): 569-575

Dodd, P.M.; Mccaffrey, J.A.; Mazumdar, M.; Scher, H.; Vlamis, V.; Higgins, G.; Herr, H.; Bajorin, D.F. 1999: Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Cancer 85(5): 1145-1150

Husain, A.; Sabbatini, P.; Spriggs, D.; Fennelly, D.; Aghajanian, C.; Barakat, R.; Curtin, J.; Venkatraman, E.; Hoskins, W.; Markman, M. 1999: Phase Ii trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. Gynecologic Oncology 73(1): 96-101

Nemunaitis, J.; Khuri, F.; Ganly, I.; Arseneau, J.; Posner, M.; Vokes, E.; Kuhn, J.; McCarty, T.; Landers, S.; Blackburn, A.; Romel, L.; Randlev, B.; Kaye, S.; Kirn, D. 2001: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(2): 289-298

Delioukina, M.L.; Prager, D.; Parson, M.; Hecht, J.Randolph.; Rosen, P.; Rosen, L.S. 2002: Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer 94(8): 2174-2179

Socinski, M.A.; Sandler, A.B.; Israel, V.K.; Gillenwater, H.H.; Miller, L.L.; Locker, P.K.; Antonellini, A.; Elfring, G.L.; Natale, R.B. 2002: Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Cancer 95(7): 1520-1527

Berg, W.J.; Schwartz, L.; Yu, R.; Mazumdar, M.; Motzer, R.J. 2001: Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Investigational New Drugs 19(4): 317-320

Valero, V.; Buzdar, A.U.; Theriault, R.L.; Azarnia, N.; Fonseca, G.A.; Willey, J.; Ewer, M.; Walters, R.S.; Mackay, B.; Podoloff, D.; Booser, D.; Lee, L.W.; Hortobagyi, G.N. 1999: Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(5): 1425-1434

Kucuk, O.; Kilton, L.; Wade, J.L.; Blough, R.; Benson, A.B. 2000: Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia. American Journal of Clinical Oncology 23(4): 379-383

Chang, T.C.; Hsueh, S.; Lai, C.H.; Tseng, C.J.; Lee, K.F.; Huang, K.G.; Chou, H.H.; Soong, Y.K. 1999: Phase II trial of neoadjuvant chemotherapy in early-stage small cell cervical cancer. Anti-Cancer Drugs 10(7): 641-646

Clark, P.E.; Peereboom, D.M.; Dreicer, R.; Levin, H.S.; Clark, S.B.; Klein, E.A. 2001: Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57(2): 281-285

Rothenberg, M.L.; Liu, P.Y.; Wilczynski, S.; Hannigan, E.V.; Weiner, S.A.; Weiss, G.R.; Hunter, V.J.; Chapman, J.A.; Tiersten, A.; Kohler, P.C.; Alberts, D.S. 2001: Phase Ii trial of oral altretamine for consolidation of clinical complete remission in women with stage IIi epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecologic Oncology 82(2): 317-322

Meyskens, F.L.; Jacobson, J.; Nguyen, B.; Weiss, G.R.; Gandara, D.R.; MacDonald, J.S. 1998: Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Investigational New Drugs 16(2): 171-173

Smith, D.C.; Esper, P.; Strawderman, M.; Redman, B.; Pienta, K.J. 1999: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(6): 1664-1671

Poplin, E.A.; Liu, P.Y.; Delmore, J.E.; Wilczynski, S.; Moore, D.F.; Potkul, R.K.; Fine, B.A.; Hannigan, E.V.; Alberts, D.S. 1999: Phase Ii trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study. Gynecologic Oncology 74(3): 432-435

Garcia, A.A.; Leichman, C.G.; Lenz, H.J.; Baranda, J.; Lujan, R.; Casagrande, Y.; Leichman, L. 2001: Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Japanese Journal of Clinical Oncology 31(6): 275-278

Papadimitriou, C.A.; Sarris, K.; Moulopoulos, L.A.; Fountzilas, G.; Anagnostopoulos, A.; Voulgaris, Z.; Gika, D.; Giannakoulis, N.; Diakomanolis, E.; Dimopoulos, M.A. 1999: Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(3): 761-766

Feun, L.G.; Savaraj, N.; Hurley, J.; Marini, A. 2002: Phase II trial of paclitaxel and dacarbazine with filgrastim administration in advanced malignant melanoma. Cancer Investigation 20(3): 357-361

Sutton, G.; Blessing, J.A.; Ball, H. 1999: Phase Ii trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecologic Oncology 74(3): 346-349

Isla, D.; Rosell, R.; Sánchez, J.J.; Carrato, A.; Felip, E.; Camps, C.; Artal, A.; González-Larriba, J.L.; Azagra, P.; Alberola, V.; Martin, C.; Massutí, B. 2001: Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(4): 1071-1077

Smith, D.C.; Chay, C.H.; Dunn, R.L.; Fardig, J.; Esper, P.; Olson, K.; Pienta, K.J. 2003: Phase Ii trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 98(2): 269-276

Pivot, X.; Chevreau, C.; Cupissol, D.; Lortholary, A.; Bui, N-Binh.; Eymard, J-Christophe.; Bay, J-Olivier.; Baranzelli, M-Christine.; Mita, M.; Barnouin, L.; Savary, J.; Thyss, A. 2002: Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma. American Journal of Clinical Oncology 25(6): 561-564

Winquist, E.; Ernst, D.S.; Jonker, D.; Moore, M.J.; Segal, R.; Lockwood, G.; Rodgers, A. 2003: Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract. European Journal of Cancer 39(13): 1866-1871

Buckner, J.C.; Peethambaram, P.P.; Smithson, W.A.; Groover, R.V.; Schomberg, P.J.; Kimmel, D.W.; Raffel, C.; O'Fallon, J.R.; Neglia, J.; Shaw, E.G. 1999: Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(3): 933-940

Edelman, M.J.; Meyers, F.J.; Grennan, T.; Lauder, J.; Doroshow, J. 1998: Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer. Investigational New Drugs 16(2): 179-182

Dodd, P.M.; Mccaffrey, J.A.; Mazumdar, M.; Icasiano, E.; Higgins, G.; Herr, H.; Bajorin, D.F. 2000: Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. Investigational New Drugs 18(3): 247-251

Bastasch, M.; Panella, T.J.; Kretzschmer, S.L.; Graham, D.; Mayo, M.; Williamson, S. 2002: Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study. Investigational New Drugs 20(3): 339-342

Vuky, J.; Mccaffrey, J.; Ginsberg, M.; Mariani, T.; Bajorin, D.F.; Bosl, G.J.; Motzer, R.J. 2000: Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Investigational New Drugs 18(3): 265-267

Plaxe, S.C.; Blessing, J.A.; Husseinzadeh, N.; Webster, K.D.; Rader, J.S.; Dunton, C.J. 2002: Phase Ii trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecologic Oncology 84(2): 241-244

Plaxe, S.C.; Blessing, J.A.; Morgan, M.A.; Carlson, J. 2002: Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. American Journal of Clinical Oncology 25(1): 45-47

Plaxe, S.C.; Blessing, J.A.; Bookman, M.A.; Creasman, W.T. 2002: Phase Ii trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 84(1): 32-35

Matlaga, B.R.; Zagoria, R.J.; Woodruff, R.D.; Torti, F.M.; Hall, M.Craig. 2002: Phase II trial of radio frequency ablation of renal cancer: Evaluation of the kill zone. Journal of Urology 168(6): 2401-2405

Whitehead, R.P.; Lew, D.; Flanigan, R.C.; Weiss, G.R.; Roy, V.; Glode, M.L.; Dakhil, S.R.; Crawford, E.D. 2002: Phase Ii trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. Journal of ImmunoTherapy 25(4): 352-358

Whitehead, R.P.; Unger, J.M.; Goodwin, J.W.; Walker, M.J.; Thompson, J.A.; Flaherty, L.E.; Sondak, V.K. 1998: Phase Ii trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. Journal of ImmunoTherapy 21(6): 440-446

Rohatgi, N.; LaRocca, R.V.; Bard, V.; Sethuraman, G.; Foon, K.A. 2002: Phase Ii trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. American Journal of Hematology 70(3): 181-185

Markman, M.; Glass, T.; Smith, H.O.; Hatch, K.D.; Weiss, G.R.; Taylor, S.A.; Goodwin, J.Wendall.; Alberts, D.S. 2003: Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: A Southwest Oncology Group trial. Gynecologic Oncology 88(3): 282-288

Lundin, J.; Kimby, E.; Björkholm, M.; Broliden, P-Anders.; Celsing, F.; Hjalmar, V.; Möllgård, L.; Rebello, P.; Hale, G.; Waldmann, H.; Mellstedt, Håkan.; Osterborg, A. 2002: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100(3): 768-773

Soori, G.; Dillman, R.O.; Wiemann, M.C.; Stark, J.J.; Tai, F.; DePriest, C.B.; Church, C.K.; Schulof, R. 2002: Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10. Cancer BioTherapy and Radiopharmaceuticals 17(2): 165-173

Chi, K.H.; Myers, J.N.; Chow, K.C.; Chan, W.K.; Tsang, Y.W.; Chao, Y.; Yen, S.H.; Lotze, M.T. 2001: Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 60(2): 110-115

Kushner, B.H.; Kramer, K.; Cheung, N.K. 2001: Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(22): 4189-4194

Fine, H.A.; Figg, W.D.; Jaeckle, K.; Wen, P.Y.; Kyritsis, A.P.; Loeffler, J.S.; Levin, V.A.; Black, P.M.; Kaplan, R.; Pluda, J.M.; Yung, W.K. 2000: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(4): 708-715

Murad, A.M.; Petroianu, A.; Guimaraes, R.C.; Aragao, B.C.; Cabral, L.O.; Scalabrini-Neto, A.O. 1999: Phase Ii trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. American Journal of Clinical Oncology 22(6): 580-586

Murad, A.M.; Guimarães, R.C.; Aragão, B.C.; Rodrigues, Víctor.H.; Scalabrini-Neto, A.O.; Padua, C.A.J.; Moore, F.C. 2003: Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. American Journal of Clinical Oncology 26(2): 151-154

Murad, A.M.; Guimarães, R.C.; Aragão, B.C.; Scalabrini-Neto, A.O.; Rodrigues, V.H.; Garcia, R. 2001: Phase Ii trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. American Journal of Clinical Oncology 24(3): 264-268

Kindler, H.L.; Kris, M.G.; Smith, I.E.; Miller, V.A.; Grant, S.C.; Krebs, J.B.; Ross, G.A.; Slevin, M.L. 1998: Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. American Journal of Clinical Oncology 21(5): 438-441

Fiorica, J.; Holloway, R.; Ndubisi, B.; Orr, J.; Grendys, E.; Boothby, R.; DeCesare, S.; LaPolla, J.; Hoffman, M.; Patel, J. 2002: Phase Ii trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecologic Oncology 85(1): 89-94

Maksymiuk, A.W.; Marschke, R.F.; Tazelaar, H.D.; Grill, J.; Nair, S.; Marks, R.S.; Brooks, B.J.; Mailliard, J.A.; Burton, G.M.; Jett, J.R. 1998: Phase Ii trial of topotecan for the treatment of mesothelioma. American Journal of Clinical Oncology 21(6): 610-613

Levine, E.G.; Cirrincione, C.T.; Szatrowski, T.P.; Canellos, G.; Norton, L.; Henderson, I.C. 1999: Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. American Journal of Clinical Oncology 22(3): 218-222

Miller, D.S.; Blessing, J.A.; Kilgore, L.C.; Mannel, R.; Van Le, L. 2000: Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. American Journal of Clinical Oncology 23(4): 355-357

Stein, S.; Zoltick, B.; Peacock, T.; Holroyde, C.; Haller, D.; Armstead, B.; Malkowicz, S.B.; Vaughn, D.J. 2001: Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial. American Journal of Clinical Oncology 24(3): 283-285

Ramanathan, R.K.; Lipsitz, S.; Asbury, R.F.; Qazi, R.; Greenberg, B.R.; Haller, D.G. 1999: Phase II trial of trimetrexate for patients with advanced gastric carcinoma: An Eastern Cooperative Oncology Group Study (E1287). Cancer 86(4): 572-576

Hartmann, J.T.; Oechsle, K.; Mayer, F.; Kanz, L.; Bokemeyer, C. 2003: Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Research 23(2c): 1899-1901

Voravud, N.; Suwanrusmee, H. 2000: Phase II trial of tropisetron and dexamethasone in the prevention of cisplatin-induced emesis. Journal of the Medical Association of Thailand 83(6): 668-675

Mani, S.; Sciortino, D.; Samuels, B.; Arrietta, R.; Schilsky, R.L.; Vokes, E.E.; Benner, S. 1999: Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Investigational New Drugs 17(1): 97-101

Scheibenbogen, C.; Schmittel, A.; Keilholz, U.; Allgäuer, T.; Hofmann, U.; Max, R.; Thiel, E.; Schadendorf, D. 2000: Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. Journal of Immunotherapy 23(2): 275-281

Lhommé, C.; Vermorken, J.B.; Mickiewicz, E.; Chevalier, B.; Alvarez, A.; Mendiola, C.; Pawinski, A.; Lentz, M.A.; Pecorelli, S. 2000: Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study. European Journal of Cancer 36(2): 194-199

Burger, R.A.; DiSaia, P.J.; Roberts, J.A.; O'rourke, M.; Gershenson, D.M.; Homesley, H.D.; Lichtman, S.M.; Barnes, W.; Moore, D.H.; Monk, B.J. 1999: Phase Ii trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecologic Oncology 72(2): 148-153

Orecchia, R.; Jereczek-Fossa, B.A.; Catalano, G.; Chiesa, F.; De Pas, T.; Masci, G.; Krengli, M.; Vavassori, A.; De Paoli, F.; Robertson, C.; Marrocco, E.; De Braud, F.; DePas, T. 2002: Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer. Oncology 63(2): 115-123

Lilenbaum, R.C.; Schwartz, M.A.; Seigel, L.; Belette, F.; Blaustein, A.; Wittlin, F.N.; Davila, E. 2001: Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 92(8): 2158-2163

Neri, B.; Doni, L.; Gemelli, M.T.; Fulignati, C.; Turrini, M.; Di Cello, V.; Dominici, A.; Maleci, M.; Mottola, A.; Ponchietti, R.; Raugei, A.; Valsuani, G.; Cini, G. 2002: Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. Journal of Urology 168(3): 956-958

Rini, B.I.; Vogelzang, N.J.; Dumas, M.C.; Wade, J.L.; Taber, D.A.; Stadler, W.M. 2000: Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(12): 2419-2426

Ilson, D.H.; Saltz, L.; Enzinger, P.; Huang, Y.; Kornblith, A.; Gollub, M.; O'Reilly, E.; Schwartz, G.; DeGroff, J.; Gonzalez, G.; Kelsen, D.P. 1999: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(10): 3270-3275

Coudert, B.; Anthoney, A.; Fiedler, W.; Droz, J.P.; Dieras, V.; Borner, M.; Smyth, J.F.; Morant, R.; de Vries, M.J.; Roelvink, M.; Fumoleau, P. 2001: Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. European Journal of Cancer 37(17): 2194-2198

Chantada, G.L.; Fandiño, A.; Mato, G.; Casak, S. 1999: Phase II window of idarubicin in children with extraocular retinoblastoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(6): 1847-1850

Wadler, S.; Damle, S.; Haynes, H.; Kaleya, R.; Schechner, R.; Berkenblit, R.; Ladner, R.D.; Murgo, A. 1999: Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(6): 1771-1778

Pilepich, M.V.; Winter, K.; John, M.J.; Mesic, J.B.; Sause, W.; Rubin, P.; Lawton, C.; Machtay, M.; Grignon, D. 2001: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. International Journal of Radiation Oncology Biology Physics 50(5): 1243-1252

Jin Xingquan; Zhao Tiping 2002: Phase III clinical trial of Carmofur. Zhongguo Zhongliu Linchuang 29(7): 501-503

Creagan, E.T.; Suman, V.J.; Dalton, R.J.; Pitot, H.C.; Long, H.J.; Veeder, M.H.; Vukov, A.M.; Rowland, K.M.; Krook, J.E.; Michalak, J.C. 1999: Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(6): 1884-1890

Gatzemeier, U.; von Pawel, J.; Gottfried, M.; ten Velde, G.P.; Mattson, K.; de Marinis, F.; Harper, P.; Salvati, F.; Robinet, G.; Lucenti, A.; Bogaerts, J.; Gallant, G. 2000: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(19): 3390-3399

Norris, B.; Pritchard, K.I.; James, K.; Myles, J.; Bennett, K.; Marlin, S.; Skillings, J.; Findlay, B.; Vandenberg, T.; Goss, P.; Latreille, J.; Rudinskas, L.; Lofters, W.; Trudeau, M.; Osoba, D.; Rodgers, A. 2000: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(12): 2385-2394

Forastiere, A.A.; Leong, T.; Rowinsky, E.; Murphy, B.A.; Vlock, D.R.; DeConti, R.C.; Adams, G.L. 2001: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(4): 1088-1095

Bonner, J.A.; Sloan, J.A.; Shanahan, T.G.; Brooks, B.J.; Marks, R.S.; Krook, J.E.; Gerstner, J.B.; Maksymiuk, A.; Levitt, R.; Mailliard, J.A.; Tazelaar, H.D.; Hillman, S.; Jett, J.R. 1999: Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(9): 2681-2691

Okuno, S.H.; Woodhouse, C.O.; Loprinzi, C.L.; Sloan, J.A.; LaVasseur, B.I.; Clemens-Schutjer, D.; Swan, D.; Axvig, C.; Ebbert, L.P.; Tirona, M.R.; Michalak, J.C.; Pierson, N. 1999: Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology 22(3): 258-261

Brouwer, R.E.; Vellenga, E.; Zwinderman, K.H.; Bezwoda, W.R.; Durrant, S.T.; Herrmann, R.P.; Kiese, B.; Maraninchi, D.; Milligan, D.W.; Sklenar, I.; Tabilio, A.; Volonte, J.L.; Winfield, D.A.; Fibbe, W.E. 1999: Phase III efficacy study of interleukin-3 after autologous bone marrow transplantation in patients with malignant lymphoma. British Journal of Haematology 106(3): 730-736

Hammack, J.E.; Michalak, J.C.; Loprinzi, C.L.; Sloan, J.A.; Novotny, P.J.; Soori, G.S.; Tirona, M.Tria.; Rowland, K.M.; Stella, P.J.; Johnson, J.A. 2002: Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98(1-2): 195-203

Bantle, J.A.; Finch, R.A.; Fort, D.J.; Stover, E.L.; Hull, M.; Kumsher-King, M.; Gaudet-Hull, A.M. 1999: Phase III interlaboratory study of FETAX. Part 3. FETAX validation using 12 compounds with and without an exogenous metabolic activation system. Journal of Applied Toxicology: Jat 19(6): 447-472

Giacchetti, S.; Perpoint, B.; Zidani, R.; Le Bail, N.; Faggiuolo, R.; Focan, C.; Chollet, P.; Llory, J.F.; Letourneau, Y.; Coudert, B.; Bertheaut-Cvitkovic, F.; Larregain-Fournier, D.; Le Rol, A.; Walter, S.; Adam, R.; Misset, J.L.; Lévi, F. 2000: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(1): 136-147

Chapman, P.B.; Einhorn, L.H.; Meyers, M.L.; Saxman, S.; Destro, A.N.; Panageas, K.S.; Begg, C.B.; Agarwala, S.S.; Schuchter, L.M.; Ernstoff, M.S.; Houghton, A.N.; Kirkwood, J.M. 1999: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(9): 2745-2751

Press, O.W.; LeBlanc, M.; Lichter, A.S.; Grogan, T.M.; Unger, J.M.; Wasserman, T.H.; Gaynor, E.R.; Peterson, B.A.; Miller, T.P.; Fisher, R.I. 2001: Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(22): 4238-4244

Andre, M.; Baudoux, E.; Bron, D.; Canon, J.L.; D'hondt, V.; Fassotte, M.F.; D'hondt, L.; Fillet, G.; Humblet, Y.; Jerusalem, G.; Vermeulen, P.; Symann, M.; Beguin, Y. 2003: Phase III randomized study comparing 5 or 10 mug per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 43(1): 50-57

Muggia, F.M.; Braly, P.S.; Brady, M.F.; Sutton, G.; Niemann, T.H.; Lentz, S.L.; Alvarez, R.D.; Kucera, P.R.; Small, J.M. 2000: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(1): 106-115

Sculier, J.P.; Lafitte, J.J.; Paesmans, M.; Thiriaux, J.; Alexopoulos, C.G.; Baumöhl, J.; Schmerber, J.; Koumakis, G.; Florin, M.C.; Zacharias, C.; Berghmans, T.; Mommen, P.; Ninane, V.; Klastersky, J. 2000: Phase IIi randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. British Journal of Cancer 83(9): 1128-1135

Buzdar, A.; Hayes, D.; El-Khoudary, A.; Yan, S.; Lønning, P.; Lichinitser, M.; Gopal, R.; Falkson, G.; Pritchard, K.; Lipton, A.; Wolter, K.; Lee, A.; Fly, K.; Chew, R.; Alderdice, M.; Burke, K.; Eisenber, P. 2002: Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Research and Treatment 73(2): 161-175

Miller, R.G.; Moore, D.H.; Gelinas, D.F.; Dronsky, V.; Mendoza, M.; Barohn, R.J.; Bryan, W.; Ravits, J.; Yuen, E.; Neville, H.; Ringel, S.; Bromberg, M.; Petajan, J.; Amato, A.A.; Jackson, C.; Johnson, W.; Mandler, R.; Bosch, P.; Smith, B.; Graves, M.; Ross, M.; Sorenson, E.J.; Kelkar, P.; Parry, G.; Olney, R. 2001: Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 56(7): 843-848

Milla-Santos, A.; Milla, L.; Rallo, L.; Solano, V. 2001: Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Research and Treatment 65(2): 119-124

Leaf, A.N.; Propert, K.; Corcoran, C.; Catalano, P.J.; Trump, D.L.; Harris, J.E.; Davis, T.E. 2003: Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Medical Oncology 20(2): 137-146

Furuse, K.; Fukuoka, M.; Kawahara, M.; Nishikawa, H.; Takada, Y.; Kudoh, S.; Katagami, N.; Ariyoshi, Y. 1999: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(9): 2692-2699

Angel, J.B.; High, K.; Rhame, F.; Brand, D.; Whitmore, J.B.; Agosti, J.M.; Gilbert, M.J.; Deresinski, S. 2000: Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group. AIDS 14(4): 387-395

Coleman, C.Norman.; Kelly, L.; Riese Daly, N.; Beard, C.; Kaplan, I.; Lamb, C.; Propert, K.; Manola, J. 2002: Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects. International Journal of Radiation Oncology Biology Physics 54(1): 191-194

Berry, W.; Dakhil, S.; Modiano, M.; Gregurich, M.; Asmar, L. 2002: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. Journal of Urology 168(6): 2439-2443

Schild, S.E.; Stella, P.J.; Geyer, S.M.; Bonner, J.A.; Marks, R.S.; Mcginnis, W.L.; Goetz, S.P.; Kuross, S.A.; Mailliard, J.A.; Kugler, J.W.; Schaefer, P.L.; Jett, J.R. 2002: Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics 54(2): 370-378

Piccart, M.J.; Di Leo, A.; Beauduin, M.; Vindevoghel, A.; Michel, J.; Focan, C.; Tagnon, A.; Ries, F.; Gobert, P.; Finet, C.; Closon-Dejardin, M.T.; Dufrane, J.P.; Kerger, J.; Liebens, F.; Beauvois, S.; Bartholomeus, S.; Dolci, S.; Lobelle, J.P.; Paesmans, M.; Nogaret, J.M. 2001: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(12): 3103-3110

Prados, M.D.; Wara, W.M.; Sneed, P.K.; McDermott, M.; Chang, S.M.; Rabbitt, J.; Page, M.; Malec, M.; Davis, R.L.; Gutin, P.H.; Lamborn, K.; Wilson, C.B.; Phillips, T.L.; Larson, D.A. 2001: Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics 49(1): 71-77

Danson, S.; Middleton, M.R.; O'Byrne, K.J.; Clemons, M.; Ranson, M.; Hassan, J.; Anderson, H.; Burt, P.A.; Fairve-Finn, C.; Stout, R.; Dowd, I.; Ashcroft, L.; Beresford, C.; Thatcher, N. 2003: Phase IIi trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 98(3): 542-553

Sandler, A.B.; Nemunaitis, J.; Denham, C.; von Pawel, J.; Cormier, Y.; Gatzemeier, U.; Mattson, K.; Manegold, C.; Palmer, M.C.; Gregor, A.; Nguyen, B.; Niyikiza, C.; Einhorn, L.H. 2000: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(1): 122-130

Inoue, T.; Inoue, T.; Yoshida, K.; Yoshioka, Y.; Shimamoto, S.; Tanaka, E.; Yamazaki, H.; Shimizutani, K.; Teshima, T.; Furukawa, S. 2001: Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer. International Journal of Radiation Oncology Biology Physics 51(1): 171-175

Motzer, R.J.; Murphy, B.A.; Bacik, J.; Schwartz, L.H.; Nanus, D.M.; Mariani, T.; Loehrer, P.; Wilding, G.; Fairclough, D.L.; Cella, D.; Mazumdar, M. 2000: Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(16): 2972-2980

Markman, M.; Bundy, B.N.; Alberts, D.S.; Fowler, J.M.; Clark-Pearson, D.L.; Carson, L.F.; Wadler, S.; Sickel, J. 2001: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(4): 1001-1007

Imadalou, K.; Cvitkovic, E. 1999: Phase III trials in oncology. Bulletin du Cancer 86(2): 143-147

Buzdar, A.; Douma, J.; Davidson, N.; Elledge, R.; Morgan, M.; Smith, R.; Porter, L.; Nabholtz, J.; Xiang, X.; Brady, C. 2001: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(14): 3357-3366

Lacey, C.J.; Thompson, H.S.; Monteiro, E.F.; O'Neill, T.; Davies, M.L.; Holding, F.P.; Fallon, R.E.; Roberts, J.S. 1999: Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. Journal of Infectious Diseases 179(3): 612-618

Rosenthal, E.; Poizot-Martin, I.; Saint-Marc, T.; Spano, J-Philippe.; Cacoub, P. 2002: Phase IV study of liposomal daunorubicin (Dauno Xome) in AIDS-related Kaposi sarcoma. American Journal of Clinical Oncology 25(1): 57-59

L.H.ng Zhou; Weng Xin Hua; Pang Mao Yin 2002: Phase IV trials of cefepime in treatment of various moderate or severe bacterial infections. Zhongguo Xinyao yu Linchuang Zazhi 21(5): 268-270

Nemoto, K.; Shibamoto, Y.; Ohmagari, J.; Baba, Y.; Ebe, K.; Ariga, H.; Takai, Y.; Ouchi, A.; Sasai, K.; Shinozaki, M.; Tsujitani, M.; Sakaguchi, M.; Yamada, S.; Sakamoto, K. 2001: Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy. Anti-Cancer Drugs 12(1): 1-6

Margolin, K.; Gordon, M.S.; Holmgren, E.; Gaudreault, J.; Novotny, W.; Fyfe, G.; Adelman, D.; Stalter, S.; Breed, J. 2001: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(3): 851-856

Varghese, T.; Bilgen, M.; Ophir, J. 2001: Phase aberration effects in elastography. Ultrasound in Medicine and Biology 27(6): 819-827

Danilenko, K.V.; Wirz-Justice, A.; Kräuchi, K.; Cajochen, C.; Weber, J.M.; Fairhurst, S.; Terman, M. 2000: Phase advance after one or three simulated dawns in humans. Chronobiology International 17(5): 659-668

Carrier, J.; Paquet, J.; Morettini, J.; Touchette, E. 2002: Phase advance of sleep and temperature circadian rhythms in the middle years of life in humans. Neuroscience Letters 320(1-2): 1-4

Warman, V.L.; Dijk, D.Jan.; Warman, G.R.; Arendt, J.; Skene, D.J. 2003: Phase advancing human circadian rhythms with short wavelength light. Neuroscience Letters 342(1-2): 37-40

Luzardo, M.C.; Bernik, D.L.; Pazos, I.F.; Figueroa, S.; Lanio, M.E.; Vérez, V.; Disalvo, E.A. 1999: Phase and surface properties of lipid bilayers containing neoglycolipids. Archives of Biochemistry and Biophysics 363(1): 81-90

Kirchhof, P.F.; Larissa Fabritz, C.; Franz, M.R. 1998: Phase angle convergence of multiple monophasic action potential recordings precedes spontaneous termination of ventricular fibrillation. Basic Research in Cardiology 93(5): 412-421

Repp, B.H. 2003: Phase attraction in sensorimotor synchronization with auditory sequences: effects of single and periodic distractors on synchronization accuracy. Journal of Experimental Psychology. Human Perception and Performance 29(2): 290-309

Johnsson, M.; Edwards, K. 2001: Phase behavior and aggregate structure in mixtures of dioleoylphosphatidylethanolamine and poly(ethylene glycol)-lipids. Biophysical Journal 80(1): 313-323

Van Malssen, K.; Van Langevelde, A.; Peschar, R.; Schenk, H. 1999: Phase behavior and extended phase scheme of static cocoa butter investigated with real-time X-ray powder diffraction. Journal of the American Oil Chemists' Society 76(6): 669-676

Shalaev, E.Y.; Steponkus, P.L. 2001: Phase behavior and glass transition of 1,2-dioleoylphosphatidylethanolamine (DOPE) dehydrated in the presence of sucrose. Biochimica et Biophysica Acta 1514(1): 100-116

Pedersen, T.B.; Frokjaer, S.; Mouritsen, O.G.; Jorgensen, K. 1999: Phase behavior and lipid-membrane structure of phospholipid-glycosphingolipid liposomes and the thermal unfolding of insulin. Journal of Liposome Research 9(2): 261-274

Chan, C-Kuang.; Chu, I-Ming. 2002: Phase behavior and miscibility in blends of poly(sebacic anhydride)/poly(ethylene glycol). Biomaterials 23(11): 2353-2358

Carrer, D.C.; Maggio, B. 1999: Phase behavior and molecular interactions in mixtures of ceramide with dipalmitoylphosphatidylcholine. Journal of Lipid Research 40(11): 1978-1989

Xiao, J.X.; Sivars, U.; Tjerneld, F. 2000: Phase behavior and protein partitioning in aqueous two-phase systems of cationic--anionic surfactant mixtures. Journal of Chromatography. B, Biomedical Sciences and Applications 743(1-2): 327-338

Karlson, L.; Joabsson, F.; Thuresson, K. 2000: Phase behavior and rheology in water and in model paint formulations thickened with HM-EHEC: Influence of the chemical structure and the distribution of hydrophobic tails. Carbohydrate Polymers 41(1): 25-35

Ismail, Z.; Kassim, A.; Suhaimi, H.; Ahmad, S. 2002: Phase behavior and rheology of mixed nonionic sugar-based surfactants. Journal of Dispersion Science and Technology 23(6): 769-776

Matuoka, S.; Akiyama, M.; Yamada, H.; Tsuchihashi, K.; Gasa, S. 2003: Phase behavior in multilamellar vesicles of DPPC containing ganglioside GM3 with a C18:1 sphingoid base and a 24:0 acyl chain (GM3(18,24)) observed by X-ray diffraction. Chemistry and Physics of Lipids 123(1): 19-29

Clogston, J.; Rathman, J.; Tomasko, D.; Walker, H.; Caffrey, M. 2000: Phase behavior of a monoacylglycerol: (myverol 18-99K)/water system. Chemistry and Physics of Lipids 107(2): 191-220

Zuhorn, I.S.; Oberle, V.; Visser, W.H.; Engberts, J.B.F.N.; Bakowsky, U.; Polushkin, E.; Hoekstra, D. 2002: Phase behavior of cationic amphiphiles and their mixtures with helper lipid influences lipoplex shape, DNA translocation, and transfection efficiency. Biophysical Journal 83(4): 2096-2108

Clary, L.; Gadras, C.; Greiner, J.; Rolland, J.P.; Santaella, C.; Vierling, P.; Gulik, A. 1999: Phase behavior of fluorocarbon and hydrocarbon double-chain hydroxylated and galactosylated amphiphiles and bolaamphiphiles. Long-term shelf-stability of their liposomes. Chemistry and Physics of Lipids 99(2): 125-137

Lesieur, S.; Charon, D.; Lesieur, P.; Ringard-Lefebvre, C.; Muguet, V.; Duchêne, D.; Wouessidjewe, D. 2000: Phase behavior of fully hydrated DMPC-amphiphilic cyclodextrin systems. Chemistry and Physics of Lipids 106(2): 127-144

Inoue, T.; Kitahashi, T.; Nibu, Y. 1999: Phase behavior of hydrated bilayer of binary phospholipid mixtures composed of 1,2-distearoylphosphatidylcholine and 1-stearoyl-2-oleoylphosphatidylcholine or 1-oleoyl-2-stearoylphosphatidylcholine. Chemistry and Physics of Lipids 99(1): 103-109

Inoue, T.; Nibu, Y. 1999: Phase behavior of hydrated lipid bilayer composed of binary mixture of phospholipids with different head groups. Chemistry and Physics of Lipids 100(1-2): 139-150

Bouwstra, J.A.; Gooris, G.S.; Dubbelaar, F.E.; Ponec, M. 2001: Phase behavior of lipid mixtures based on human ceramides: coexistence of crystalline and liquid phases. Journal of Lipid Research 42(11): 1759-1770

Bouwstra, J.A.; Gooris, G.S.; Dubbelaar, F.E.R.; Ponec, M. 2002: Phase behavior of stratum corneum lipid mixtures based on human ceramides: the role of natural and synthetic ceramide 1. Journal of Investigative Dermatology 118(4): 606-617

Qiu, H.; Caffrey, M. 1999: Phase behavior of the monoerucin/water system. Chemistry and Physics of Lipids 100(1-2): 55-79

Simberg, D.; Danino, D.; Talmon, Y.; Minsky, A.; Ferrari, M.E.; Wheeler, C.J.; Barenholz, Y. 2001: Phase behavior, DNA ordering, and size instability of cationic lipoplexes. Relevance to optimal transfection activity. Journal of Biological Chemistry 276(50): 47453-47459

Tolstoguzov, V. 2000: Phase behaviour of macromolecular components in biological and food systems. Die Nahrung 44(5): 299-308

Tunstall, M.E.; Ross, J.A. 2002: Phase behaviour of premixed 0.25% isoflurane in 50% nitrous oxide and 50% oxygen. British Journal of Anaesthesia 89(6): 814-819

Schorsch, C.; Jones, M.G.; Norton, I.T. 2000: Phase behaviour of pure micellar casein/kappa-carrageenan systems in milk salt ultrafiltrate. Food Hydrocolloids 14(4): 347-358

Bouwsta, J.A.; Gooris, G.S.; Dubbelaar, F.E.; Ponec, M. 2000: Phase behaviour of skin barrier model membranes at pH 7.4. Cellular and Molecular Biology 46(5): 979-992

Lichtenberg, D.; Opatowski, E.; Kozlov, M.M. 2000: Phase boundaries in mixtures of membrane-forming amphiphiles and micelle-forming amphiphiles. Biochimica et Biophysica Acta 1508(1-2): 1-19

Bernazzani, P.; Chapados, C.; Delmas, G. 2001: Phase change in amylose-water mixtures as seen by Fourier transform infrared. Biopolymers 58(3): 305-318

Smith, G.D.; Pangborn, W.A.; Blessing, R.H. 2001: Phase changes in T(3)R(3)(f) human insulin: temperature or pressure induced?. Acta Crystallographica. Section D Biological Crystallography 57(Pt 8): 1091-1100

Asai, Y. 2003: Phase characteristics of dispersed particles composed of retinal and dipalmitoylphosphatidylcholine. Yakuzaigaku 63(2): 79-88

Thiel, T.; Czisch, M.; Elbel, G.K.; Hennig, J. 2002: Phase coherent averaging in magnetic resonance spectroscopy using interleaved navigator scans: compensation of motion artifacts and magnetic field instabilities. Magnetic Resonance in Medicine 47(6): 1077-1082

Damke, H.; Henning, K.H.; Lehmann, J.; Kasbohm, J.; Puff, T. 1999: Phase composition of flood sediments of the German-Polish Odra river immediately after the flood event in 1997. Acta Hydrochimica et Hydrobiologica 27(5): 357-363

Reese, T.G.; Feinberg, D.A.; Dou, J.; Wedeen, V.J. 2002: Phase contrast MRI of myocardial 3D strain by encoding contiguous slices in a single shot. Magnetic Resonance in Medicine 47(4): 665-676

Kotre, C.J.; Birch, I.P. 1999: Phase contrast enhancement of x-ray mammography: A design study. Physics in Medicine and Biology 44(11): 2853-2866

Repp, B.H. 2002: Phase correction following a perturbation in sensorimotor synchronization depends on sensory information. Journal of Motor Behavior 34(3): 291-298

Repp, B.H. 2002: Phase correction in sensorimotor synchronization: Nonlinearities in voluntary and involuntary responses to perturbations. Human Movement Science 21(1): 1-37

Post, E.; Stenseth, N.C.; Peterson, R.O.; Vucetich, J.A.; Ellis, A.M. 2002: Phase dependence and population cycles in a large-mammal predator-prey system. Ecology Washington D C 83(11): 2997-3002

Shinohara, K.; Tominaga, K.; Inouye, S.T. 1999: Phase dependent response of vasoactive intestinal polypeptide to light and darkness in the suprachiasmatic nucleus. Neuroscience Research 33(2): 105-110

Hreljac, A.; Stergiou, N. 2000: Phase determination during normal running using kinematic data. Medical and Biological Engineering and Computing 38(5): 503-506

Koltover, I.; Salditt, T.; Safinya, C.R. 1999: Phase diagram, stability, and overcharging of lamellar cationic lipid-DNA self-assembled complexes. Biophysical Journal 77(2): 915-924

Rösgen, Jörg.; Hinz, H-Jürgen. 2003: Phase diagrams: A graphical representation of linkage relations. Journal of Molecular Biology 328(1): 255-271

Schaap, J.; Albus, H.; Eilers, P.H.; Détári, L.; Meijer, J.H. 2001: Phase differences in electrical discharge rhythms between neuronal populations of the left and right suprachiasmatic nuclei. Neuroscience 108(3): 359-363

Mimeault, D.; Lepore, F.; Guillemot, J-Paul. 2002: Phase disparity in area 19 of the cat. Neuroreport 13(3): 291-296

Alves, M.M.; Antonov, Y.A.; Gonçalves, M.P. 2000: Phase equilibria and mechanical properties of gel-like water-gelatin-locust bean gum systems. International Journal of Biological Macromolecules 27(1): 41-47

Moretti, J.J.; Sandler, S.I.; Lenhoff, A.M. 2000: Phase equilibria in the lysozyme-ammonium sulfate-water system. Biotechnology and Bioengineering 70(5): 498-506

Seifert, H.-Juergen; Peng, J.; Golczewski, J.; Aldinger, F. 2001: Phase equilibria of precursor-derived Si-(B-)C-N ceramics. Applied Organometallic Chemistry 15(10): 794-808

Silva, L.-De; Meirelles, A. 2001: Phase equilibrium and protein partitioning in aqueous mixtures of maltodextrin with polypropylene glycol. Carbohydrate polymers 46(3): 267-274

Yuan, C.; Johnston, L.J. 2002: Phase evolution in cholesterol/DPPC monolayers: Atomic force microscopy and near field scanning optical microscopy studies. Journal of Microscopy 205(Pt 2): 136-146

Hammershoj, M.; Kjaer, J.B. 1999: Phase feeding for laying hens: Effect of protein and essential amino acids on egg quality and production. Acta Agriculturae Scandinavica Section A Animal Science 49(1): 31-41

Al-Qodah, Z.; Al-Hassan, M. 2000: Phase holdup and gas-to-liquid mass transfer coefficient in magneto stabilized G-L-S airlift fermenter. Chemical Engineering Journal 79(1): 41-52

Bohle, D.Scott.; Kosar, A.D.; Stephens, P.W. 2002: Phase homogeneity and crystal morphology of the malaria pigment beta-hematin. Acta Crystallographica. Section D Biological Crystallography 58(Pt 10 Pt 1): 1752-1756

Nagao, E.; Dvorak, J.A. 1999: Phase imaging by atomic force microscopy: analysis of living homoiothermic vertebrate cells. Biophysical Journal 76(6): 3289-3297

Graham, P.D.; Brodbeck, K.J.; Mchugh, A.J. 1999: Phase inversion dynamics of PLGA solutions related to drug delivery. Journal of Controlled Release: Official Journal of the Controlled Release Society 58(2): 233-245

Brodbeck, K.J.; Desnoyer, J.R.; Mchugh, A.J. 1999: Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. Journal of Controlled Release: Official Journal of the Controlled Release Society 62(3): 333-344

Strobel, D.; Raeker, S.; Martus, P.; Hahn, E.G.; Becker, D. 2003: Phase inversion harmonic imaging versus contrast-enhanced power Doppler sonography for the characterization of focal liver lesions. International Journal of Colorectal Disease 18(1): 63-72

Simões, C.; Jensen, O.; Parkkonen, L.; Hari, R. 2003: Phase locking between human primary and secondary somatosensory cortices. Proceedings of the National Academy of Sciences of the United States of America 100(5): 2691-2694

Huber, M.; Lindgren, M.; Hammarstrom, P.; Martensson, L.G.; Carlsson, U.; Eaton, G.R.; Eaton, S.S. 2001: Phase memory relaxation times of spin labels in human carbonic anhydrase II: Pulsed EPR to determine spin label location. Biophysical Chemistry 94(3): 245-256, 25 December

Jhooti, P.; Gatehouse, P.D.; Keegan, J.; Bunce, N.H.; Taylor, A.M.; Firmin, D.N. 2000: Phase ordering with automatic window selection (PAWS): A novel motion-resistant technique for 3D coronary imaging. Magnetic Resonance in Medicine 43(3): 470-480

Bose, A.; Recce, M. 2001: Phase precession and phase-locking of hippocampal pyramidal cells. Hippocampus 11(3): 204-215

Ahn, T.; Yun, C.H. 1999: Phase properties of liquid-crystalline Phosphatidylcholine/Phosphatidylethanolamine bilayers revealed by fluorescent probes. Archives of Biochemistry and Biophysics 369(2): 288-294

Hsieh, M.F.; Perng, L.H.; Chin, T.S.; Perng, H.G. 2001: Phase purity of sol-gel-derived hydroxyapatite ceramic. Biomaterials 22(19): 2601-2607

Aguilar Roblero, R.; Escandon Calderon, J.; Salazar Juarez, A.; Caldelas, I.; Granados Fuentes, D.; Escobar, C. 1998: Phase relations between host and grafted SCN depend on graft location in rats. Biological Rhythm Research 29(5): 521-529

Marsden, J.F.; Ashby, P.; Rothwell, J.C.; Brown, P. 2000: Phase relationships between cortical and muscle oscillations in cortical myoclonus: Electrocorticographic assessment in a single case. Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology 111(12): 2170-2174

Masino, M.A.; Calabrese, R.L. 2002: Phase relationships between segmentally organized oscillators in the leech heartbeat pattern generating network. Journal of Neurophysiology 87(3): 1572-1585

Kuhlman, S.J.; Silver, R.; Le Sauter, J.; Bult-Ito, A.; McMahon, D.G. 2003: Phase resetting light pulses induce Per1 and persistent spike activity in a subpopulation of biological clock neurons. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 23(4): 1441-1450

Mahoney, M.; Bult, A.; Smale, L. 2001: Phase response curve and light-induced fos expression in the suprachiasmatic nucleus and adjacent hypothalamus of Arvicanthis niloticus. Journal of Biological Rhythms 16(2): 149-162

Petri, B.; Stengl, M. 2001: Phase response curves of a molecular model oscillator: implications for mutual coupling of paired oscillators. Journal of Biological Rhythms 16(2): 125-141

Coster, A.C.F.; Celler, B.G. 2003: Phase response of model sinoatrial node cells. Annals of Biomedical Engineering 31(3): 271-283

Stepien, J.M.; Kennaway, D.J. 2001: Phase response relationships between light pulses and the melatonin rhythm in rats. Journal of Biological Rhythms 16(3): 234-242

Allen, L.J.; Faulkner, H.M.; Oxley, M.P.; Paganin, D. 2001: Phase retrieval and aberration correction in the presence of vortices in high-resolution transmission electron microscopy. Ultramicroscopy 88(2): 85-97

Ting, L.H.; Kautz, S.A.; Brown, D.A.; Zajac, F.E. 1999: Phase reversal of biomechanical functions and muscle activity in backward pedaling. Journal of Neurophysiology 81(2): 544-551

Pacek, A.W.; Ding, P.; Nienow, A.W.; Wedd, M. 2000: Phase separation and drop size distributions in homogeneous Na-alginate/Na-caseinate mixtures. Carbohydrate Polymers 42(4): 401-409

Lorén, N.; Hermansson, A.M. 2000: Phase separation and gel formation in kinetically trapped gelatin/maltodextrin gels. International Journal of Biological Macromolecules 27(4): 249-262

Wittmaack, K.; Menzel, N.; Wehnes, H.; Heinzmann, U. 2002: Phase separation and regrowth of aerosol matter collected after size fractionation in an impactor. Atmospheric Environment 36(39-40): 5877-5886

Closs, C.B.; Conde Petit, B.; Roberts, I.D.; Tolstoguzov, V.B.; Escher, F. 1999: Phase separation and rheology of aqueous starch/galactomannan systems. Carbohydrate Polymers 39(1): 67-77

Butler, M.F. 2002: Phase separation in a sheared gelatin/maltodextrin mixture studied by small-angle light scattering. Biomacromolecules 3(6): 1208-1216

Antonov, Y.A.; Goncalves, M.P. 1999: Phase separation in aqueous gelatin-kappa-carrageenan systems. Food Hydrocolloids 13(6): 517-524

Straatmann, A.; Borchard, W. 2003: Phase separation in calcium alginate gels. European Biophysics Journal: Ebj 32(5): 412-417

Butler, M.F.; Heppenstall-Butler, M. 2001: Phase separation in gelatin/maltodextrin and gelatin/maltodextrin/gum arabic mixtures studied using small-angle light scattering, turbidity, and microscopy. Biomacromolecules 2(3): 812-823

Discher, B.M.; Schief, W.R.; Vogel, V.; Hall, S.B. 1999: Phase separation in monolayers of pulmonary surfactant phospholipids at the air-water interface: composition and structure. Biophysical Journal 77(4): 2051-2061

Dewolf, C.; Leporatti, S.; Kirsch, C.; Klinger, R.; Brezesinski, G. 1999: Phase separation in phosphatidylinositol/phosphatidylcholine mixed monolayers. Chemistry and Physics of Lipids 97(2): 129-138

Sakurai, K.; Shinkai, S. 2000: Phase separation in the mixture of schizophyllan and poly(ethylene oxide) in aqueous solution driven by a specific interaction between the glucose side chain and poly(ethylene oxide). Carbohydrate Research 324(2): 136-140

Bach, D.; Borochov, N.; Wachtel, E. 2002: Phase separation of cholesterol and the interaction of ethanol with phosphatidylserine-cholesterol bilayer membranes. Chemistry and Physics of Lipids 114(2): 123-130

Asenjo, J.A.; Mistry, S.L.; Andrews, B.A.; Merchuk, J.C. 2002: Phase separation rates of aqueous two-phase systems: correlation with system properties. Biotechnology and Bioengineering 79(2): 217-223

Wang, X.; Quinn, P.J. 2002: Phase separations of alpha-tocopherol in aqueous dispersions of distearoylphosphatidylethanolamine. Chemistry and Physics of Lipids 114(1): 1-9

Ruby, N.F.; Joshi, N.; Heller, H.C. 1998: Phase shift magnitude and direction determine whether Siberian hamsters reentrain to the photocycle. Journal of Biological Rhythms 13(6): 506-517

Rosenwasser, A.M.; Dwyer, S.M. 2002: Phase shifting the hamster circadian clock by 15-minute dark pulses. Journal of Biological Rhythms 17(3): 238-247

Steenhard, B.M.; Besharse, J.C. 2000: Phase shifting the retinal circadian clock: xPer2 mRNA induction by light and dopamine. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 20(23): 8572-8577

Yan, L.; Hochstetler, K.J.; Silver, R.; Bult-Ito, A. 2003: Phase shifts and Per gene expression in mouse suprachiasmatic nucleus. Neuroreport 14(9): 1247-1251

Eason, J.; Trayanova, N. 2002: Phase singularities and termination of spiral wave reentry. Journal of Cardiovascular Electrophysiology 13(7): 672-679

Arani, R.B.; Soong, S.J.; Weiss, H.L.; Wood, M.J.; Fiddian, P.A.; Gnann, J.W.; Whitley, R. 2001: Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Statistics in Medicine 20(16): 2429-2439

Johnson, A.M.; Fenton, K.A.; Mercer, C. 2002: Phase specific strategies for the prevention, control, and elimination of sexually transmitted diseases: background country profile, England and Wales. Sexually Transmitted Infections 78(Suppl): I125-I132

Low, N. 2002: Phase specific strategies for the prevention, control, and elimination of sexually transmitted infections: case study in Lambeth, Southwark, and Lewisham, London, UK. Sexually Transmitted Infections 78(Suppl): I133-I138

Antonov, Y.A.; Zubova, O.M. 2001: Phase state of aqueous gelatin-polysaccharide (1)-polysaccharide (2) systems. International Journal of Biological Macromolecules 29(2): 67-71

Krikunets, V.M.; Zhmurko, N.G.; Sichkar, V.I. 1998: Phase structure of the dependence of soybean and pea yield on the dose of molybdenum. Agrokhimiya (4): 67-75

Henson, S.M.; Cushing, J.M.; Costantino, R.F.; Dennis, B.; Desharnais, R.A. 1998: Phase switching in population cycles. Proceedings of the Royal Society of London Series B Biological Sciences 265(1411): 2229-2234

Gadzinowski, M.; Slomkowski, S.; Elaïssari, A.; Pichot, C. 2000: Phase transfer and characterization of poly(epsilon-caprolactone) and poly(L-lactide) microspheres. Journal of Biomaterials Science. Polymer Edition 11(5): 459-480

Denry, I.L.; Holloway, J.A.; Colijn, H.O. 2001: Phase transformations in a leucite-reinforced pressable dental ceramic. Journal of Biomedical Materials Research 54(3): 351-359

Lee, J.; Macosko, C.W.; Urry, D.W. 2001: Phase transition and elasticity of protein-based hydrogels. Journal of Biomaterials Science. Polymer Edition 12(2): 229-242

Feitosa, E.; Barreleiro, P.C.; Olofsson, G. 2000: Phase transition in dioctadecyldimethylammonium bromide and chloride vesicles prepared by different methods. Chemistry and Physics of Lipids 105(2): 201-213

Getz, E.B.; Cooke, R.; Lehman, S.L. 1998: Phase transition in force during ramp stretches of skeletal muscle. Biophysical Journal 75(6): 2971-2983

Liu, Q.; Charlet, G.; Yelle, S.; Arul, J. 2002: Phase transition in potato starch-water system I. Starch gelatinization at high moisture level. Food Research International 35(4): 397-407

IIjima, M.; Nakamura, K.; Hatakeyama, T.; Hatakeyama, H. 2000: Phase transition of pectin with sorbed water. Carbohydrate Polymers 41(1): 101-106

Pohle, W.; Selle, C.; Rettig, W.; Heiser, U.; Dobner, B.; Wartewig, S. 2001: Phase transitions and hydrogen bonding in a bipolar phosphocholine evidenced by calorimetry and vibrational spectroscopy. Archives of Biochemistry and Biophysics 396(2): 151-161

Pollack, G.H.; Reitz, F.B. 2001: Phase transitions and molecular motion in the cell. Cellular and Molecular Biology 47(5): 885-900

Stinear, J.W.; Byblow, W.D. 2001: Phase transitions and postural deviations during bimanual kinesthetic tracking. Experimental Brain Research 137(3-4): 467-477

Lambertz, M.; Vandenhouten, R.; Grebe, R.; Langhorst, P. 2000: Phase transitions in the common brainstem and related systems investigated by nonstationary time series analysis. Journal of the Autonomic Nervous System 78(2-3): 141-157

Pyne, A.; Suryanarayanan, R. 2001: Phase transitions of glycine in frozen aqueous solutions and during freeze-drying. Pharmaceutical Research 18(10): 1448-1454

Tong, W.; Li, X.; Feng, J.; Chen, J.; Zhang, X. 2001: Phase transitions of hydroxyapatite coatings during post-heat treatment and their performances under ultrasonic tests. Journal of Biomedical Materials Research 56(1): 49-55

Sobral, P.J.A.; Habitante, A.M.Q.B. 2001: Phase transitions of pigskin gelatin. Food Hydrocolloids 15(4-6): 377-382

Stillinger, F.H.; Debenedetti, P.G. 2003: Phase transitions, Kauzmann curves, and inverse melting. Biophysical Chemistry 105(2-3): 211-220

Shafer, W.M.; Datta, A.; Kolli, V.S.Kumar.; Rahman, M.Mahbubur.; Balthazar, J.T.; Martin, L.E.; Veal, W.L.; Stephens, D.S.; Carlson, R. 2002: Phase variable changes in genes lgtA and lgtC within the lgtABCDE operon of Neisseria gonorrhoeae can modulate gonococcal susceptibility to normal human serum. Journal of Endotoxin Research 8(1): 47-58

Seib, K.L.; Peak, I.R.A.; Jennings, M.P. 2002: Phase variable restriction-modification systems in Moraxella catarrhalis. FEMS Immunology and Medical Microbiology 32(2): 159-165

Röske, K.; Blanchard, A.; Chambaud, I.; Citti, C.; Helbig, J.H.; Prevost, M.C.; Rosengarten, R.; Jacobs, E. 2001: Phase variation among major surface antigens of Mycoplasma penetrans. Infection and Immunity 69(12): 7642-7651

Appelmelk, B.J.; Martino, M.C.; Veenhof, E.; Monteiro, M.A.; Maaskant, J.J.; Negrini, R.; Lindh, F.; Perry, M.; Del Giudice, G.; Vandenbroucke-Grauls, C.M. 2000: Phase variation in H type i and Lewis a epitopes of Helicobacter pylori lipopolysaccharide. Infection and Immunity 68(10): 5928-5932

Appelmelk, B.J.; Martin, S.L.; Monteiro, M.A.; Clayton, C.A.; McColm, A.A.; Zheng, P.; Verboom, T.; Maaskant, J.J.; van den Eijnden, D.H.; Hokke, C.H.; Perry, M.B.; Vandenbroucke-Grauls, C.M.; Kusters, J.G. 1999: Phase variation in Helicobacter pylori lipopolysaccharide due to changes in the lengths of poly(C) tracts in alpha3-fucosyltransferase genes. Infection and Immunity 67(10): 5361-5366

Berrington, A.W.; Tan, Y-C.; Srikhanta, Y.; Kuipers, B.; van der Ley, P.; Peak, I.R.A.; Jennings, M.P. 2002: Phase variation in meningococcal lipooligosaccharide biosynthesis genes. FEMS Immunology and Medical Microbiology 34(4): 267-275

Tannaes, T.; Dekker, N.; Bukholm, G.; Bijlsma, J.J.; Appelmelk, B.J. 2001: Phase variation in the Helicobacter pylori phospholipase a gene and its role in acid adaptation. Infection and Immunity 69(12): 7334-7340

Haagmans, W.; Van Der Woude, M. 2000: Phase variation of Ag43 in Escherichia coli: Dam-dependent methylation abrogates OxyR binding and OxyR-mediated repression of transcription. Molecular Microbiology 35(4): 877-887

Guerry, P.; Szymanski, C.M.; Prendergast, M.M.; Hickey, T.E.; Ewing, C.P.; Pattarini, D.L.; Moran, A.P. 2002: Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro. Infection and Immunity 70(2): 787-793

Lewis, L.A.; Gipson, M.; Hartman, K.; Ownbey, T.; Vaughn, J.; Dyer, D.W. 1999: Phase variation of HpuAB and HmbR, two distinct haemoglobin receptors of Neisseria meningitidis DNM2. Molecular Microbiology 32(5): 977-989

Linton, D.; Gilbert, M.; Hitchen, P.G.; Dell, A.; Morris, H.R.; Wakarchuk, W.W.; Gregson, N.A.; Wren, B.W. 2000: Phase variation of a beta-1,3 galactosyltransferase involved in generation of the ganglioside GM1-like lipo-oligosaccharide of Campylobacter jejuni. Molecular Microbiology 37(3): 501-514

Honarvar, S.; Choi, B-Kwon.; Schifferli, D.M. 2003: Phase variation of the 987P-like CS18 fimbriae of human enterotoxigenic Escherichia coli is regulated by site-specific recombinases. Molecular Microbiology 48(1): 157-171

Norris, T.L.; Bäumler, A.J. 1999: Phase variation of the lpf operon is a mechanism to evade cross-immunity between Salmonella serotypes. Proceedings of the National Academy of Sciences of the United States of America 96(23): 13393-13398

Carson, S.D.; Stone, B.; Beucher, M.; Fu, J.; Sparling, P.F. 2000: Phase variation of the gonococcal siderophore receptor FetA. Molecular Microbiology 36(3): 585-593

Monecke, S.; Helbig, J.ür.H.; Jacobs, E. 2003: Phase variation of the multiple banded protein in Ureaplasma urealyticum and Ureaplasma parvum. International Journal of Medical Microbiology: Ijmm 293(2-3): 203-211

Neyrolles, O.; Chambaud, I.; Ferris, S.; Prevost, M.C.; Sasaki, T.; Montagnier, L.; Blanchard, A. 1999: Phase variations of the Mycoplasma penetrans main surface lipoprotein increase antigenic diversity. Infection and Immunity 67(4): 1569-1578

Stenseth, N.C.; Chan, K.S.; Framstad, E.; Tong, H. 1998: Phase- and density-dependent population dynamics in Norwegian lemmings: interaction between deterministic and stochastic processes. Proceedings. Biological Sciences 265(1409): 1957-1968

Mimeault, D.; Lepore, F.; Guillemot, J-P. 2002: Phase- and position-disparity coding in the posteromedial lateral suprasylvian area of the cat. Neuroscience 110(1): 59-72

Steinmetz, H.T.; Schulz, A.; Staib, P.; Scheid, C.; Glasmacher, A.; Neufang, A.; Franklin, J.; Tesch, H.; Diehl, V.; Dias Wickramanayake, P. 1999: Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Annals of Hematology 78(9): 418-425

Hofmann, E.; Warmuth-Metz, M.; Bendszus, M.; Solymosi, L. 2000: Phase-contrast MR imaging of the cervical CSF and spinal cord: volumetric motion analysis in patients with Chiari I malformation. Ajnr. American Journal of Neuroradiology 21(1): 151-158

Kolbitsch, C.; Schocke, M.; Lorenz, I., H.; Kremser, C.; Zschiegner, F.; Pfeiffer, K., P.; Felber, S.; Aichner, F.; Hormann, C.; Benzer, A. 1999: Phase-contrast MRI measurement of systolic cerebrospinal fluid peak velocity (CSFVPeak) in the aqueduct of Sylvius. Anesthesiology (Hagerstown) 90(6): 1546-1550

Baruchel, J.; Lodini, A.; Romanzetti, S.; Rustichelli, F.; Scrivani, A. 2001: Phase-contrast imaging of thin biomaterials. Biomaterials 22(12): 1515-1520

De Haan, M.W.; van Engelshoven, J.M.A.; Houben, A.J.H.M.; Kaandorp, D.W.; Kessels, A.G.H.; Kroon, A.A.; de Leeuw, P.W. 2003: Phase-contrast magnetic resonance flow quantification in renal arteries: comparison with 133Xenon washout measurements. Hypertension 41(1): 114-118

Barger, A.V.; Peters, D.C.; Block, W.F.; Vigen, K.K.; Korosec, F.R.; Grist, T.M.; Mistretta, C.A. 2000: Phase-contrast with interleaved undersampled projections. Magnetic Resonance in Medicine 43(4): 503-509

Skinner, F.K.; Wu, C.; Zhang, L. 2001: Phase-coupled oscillator models can predict hippocampal inhibitory synaptic connections. European Journal of Neuroscience 13(12): 2183-2194

Schack, B.; Vath, N.; Petsche, H.; Geissler, H-G.; Möller, E. 2002: Phase-coupling of theta-gamma EEG rhythms during short-term memory processing. International Journal of Psychophysiology: Official Journal of the International Organization of Psychophysiology 44(2): 143-163

Rassler, B.; Nietzold, I.; Waurick, S. 1999: Phase-dependence of breathing and finger tracking movements during normocapnia and hypercapnia. European Journal of Applied Physiology and Occupational Physiology 80(4): 324-332

Boivin, D.B.; James, F.O. 2002: Phase-dependent effect of room light exposure in a 5-h advance of the sleep-wake cycle: implications for jet lag. Journal of Biological Rhythms 17(3): 266-276

Inoue, T.; Watanabe, S.; Kawahara, S.; Kirino, Y. 2000: Phase-dependent filtering of sensory information in the oscillatory olfactory center of a terrestrial mollusk. Journal of Neurophysiology 84(2): 1112-1115

Niizeki, K.; Miyamoto, Y. 1999: Phase-dependent heartbeat modulation by muscle contractions during dynamic handgrip in humans. American Journal of Physiology 276(4): H1331-H1338

Abe, H.; Honma, S.; Namihira, M.; Tanahashi, Y.; Ikeda, M.; Yu, W.; Honma, K. 1999: Phase-dependent induction by light of rat Clock gene expression in the suprachiasmatic nucleus. Brain Research. Molecular Brain Research 66(1-2): 104-110

Garrett, M.; Kerr, T.; Caulfield, B. 1999: Phase-dependent inhibition of H-reflexes during walking in humans is independent of reduction in knee angular velocity. Journal of Neurophysiology 82(2): 747-753

Hauglustaine, S.; Prokop, T.; Van Zwieten, K.J.; Duysens, J. 2001: Phase-dependent modulation of cutaneous reflexes of tibialis anterior muscle during hopping. Brain Research 897(1-2): 180-183

Büschges, A.; Wolf, H. 1999: Phase-dependent presynaptic modulation of mechanosensory signals in the locust flight system. Journal of Neurophysiology 81(2): 959-962

Miyake, S.; Sumi, Y.; Yan, L.; Takekida, S.; Fukuyama, T.; Ishida, Y.; Yamaguchi, S.; Yagita, K.; Okamura, H. 2000: Phase-dependent responses of Per1 and Per2 genes to a light-stimulus in the suprachiasmatic nucleus of the rat. Neuroscience Letters 294(1): 41-44

Scholz, G.; Mrowinski, D.; Hensel, J. 1999: Phase-dependent suppression of transient evoked and distortion product otoacoustic emissions by a low-frequency tone. Audiology: Official Organ of the International Society of Audiology 38(5): 271-275

Mimeault, D.; Paquet, Vérie.; Lepore, F.; Guillemot, J-Paul. 2002: Phase-disparity coding in extrastriate area 19 of the cat. Journal of Physiology 545(3): 987-996

Buzady, A.; Erostyak, J.; Somogyi, B. 2000: Phase-fluorimetry study on dielectric relaxation of human serum albumin. Biophysical Chemistry 88(1-3): 153-163, 15 December

Buzády, A.; Erostyák, J.; Somogyi, B. 2001: Phase-fluorometry study on dielectric relaxation of acrylodan-labeled human serum albumin. Biophysical Chemistry 94(1-2): 75-85

Iba, K.; Chiba, H.; Yamashita, T.; Ishii, S.; Sawada, N. 2001: Phase-independent inhibition by retinoic acid of mineralization correlated with loss of tetranectin expression in a human osteoblastic cell line. Cell Structure and Function 26(4): 227-233

Malyshev, A.Y.; Norekian, T.P. 2002: Phase-locked coordination between two rhythmically active feeding structures in the mollusk Clione limacina. I. Motor neurons. Journal of Neurophysiology 87(6): 2996-3005

Wallace, M.N.; Shackleton, T.M.; Palmer, A.R. 2002: Phase-locked responses to pure tones in the primary auditory cortex. Hearing Research 172(1-2): 160-171

Karashima, A.; Nakamura, K.; Sato, N.; Nakao, M.; Katayama, N.; Yamamoto, M. 2002: Phase-locking of spontaneous and elicited ponto-geniculo-occipital waves is associated with acceleration of hippocampal theta waves during rapid eye movement sleep in cats. Brain Research 958(2): 347-358

Umemura, N. 2000: Phase-matching properties of nonlinear optical crystals: CsLiB6O10, KNbO3, and Gdx Y1-xCa4O(BO3)3. Memoirs of the Osaka Institute of Technology Series A Science and Technology 45(1): 21-38

Li, L.; Kodama, K.; Saito, K.; Aizawa, K. 2002: Phase-resolved fluorescence study of mono-L-aspartyl chlorin E6. Journal of Photochemistry and Photobiology. B Biology 67(1): 51-56

Kellman, P.; Arai, A.E.; Mcveigh, E.R.; Aletras, A.H. 2002: Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magnetic Resonance in Medicine 47(2): 372-383

Reebs, S.G.; Cormier, R. 2001: Phase-shifting effects of dusklike and dawnlike light pulses on the circadian activity rhythms of Syrian hamsters. Chronobiology International 18(3): 413-421

Zawilska, J.B.; Vivien-Roels, B.; Skene, D.J.; Pévet, P.; Nowak, J.Z. 2000: Phase-shifting effects of light on the circadian rhythms of 5-methoxytryptophol and melatonin in the chick pineal gland. Journal of Pineal Research 29(1): 1-7

Piggins, H.D.; Marchant, E.G.; Goguen, D.; Rusak, B. 2001: Phase-shifting effects of pituitary adenylate cyclase activating polypeptide on hamster wheel-running rhythms. Neuroscience Letters 305(1): 25-28

Daymude, J.A.; Refinetti, R. 1999: Phase-shifting effects of single and multiple light pulses in the golden hamster. Biological Rhythm Research 30(2): 202-215

Lague, M.; Reebs, S.G. 2000: Phase-shifting the light-dark cycle influences food-anticipatory activity in golden shiners. Physiology and Behavior 70(1-2): 55-59

Donalies, U.E.; Stahl, U. 2001: Phase-specific gene expression in Saccharomyces cerevisiae, using maltose as carbon source under oxygen-limiting conditions. Current Genetics 39(3): 150-155

Gangitano, M.; Mottaghy, F.M.; Pascual-Leone, A. 2001: Phase-specific modulation of cortical motor output during movement observation. Neuroreport 12(7): 1489-1492

Seol Yongkoo; Schwartz Franklin, W. 2000: Phase-transfer catalysis applied to the oxidation of nonaqueous phase trichloroethylene by potassium permanganate. Journal of Contaminant Hydrology 44(2): 185-201

Powell, D.A.; Ramsden, P.D.; Batey, R.A. 2003: Phase-transfer-catalyzed alkylation of guanidines by alkyl halides under biphasic conditions: A convenient protocol for the synthesis of highly functionalized guanidines. Journal of Organic Chemistry 68(6): 2300-2309

Powell, A.J.; Maier, S.E.; Chung, T.; Geva, T. 2000: Phase-velocity cine magnetic resonance imaging measurement of pulsatile blood flow in children and young adults: in vitro and in vivo validation. Pediatric Cardiology 21(2): 104-110

Katayama, S.; Matsushita, O.; Tamai, E.; Miyata, S.; Okabe, A. 2001: Phased A-tracts bind to the alpha subunit of RNA polymerase with increased affinity at low temperature. Febs Letters 509(2): 235-238

Kellman, P.; Guttman, M.A.; Herzka, D.A.; McVeigh, E.R. 2002: Phased array ghost elimination (PAGE) for segmented SSFP imaging with interrupted steady-state. Magnetic Resonance in Medicine 48(6): 1076-1080

Arntz, H.R.; Agrawal, R.; Richter, H.; Schmidt, S.; Rescheleit, T.; Menges, M.; Burbach, H.; Schröder, J.; Schultheiss, H.P. 2001: Phased chest and abdominal compression-decompression versus conventional cardiopulmonary resuscitation in out-of-hospital cardiac arrest. Circulation 104(7): 768-772

Ryder, J.J.; Griffin, C.T. 2003: Phased infectivity in Heterorhabditis megidis: The effects of infection density in the parental host and filial generation. International Journal for Parasitology 33(10): 1013-1018

Yung, A.C.; Oner, A.Y.; Serfaty, J.-M.; Feneley, M.; Yang, X.; Atalar, E. 2003: Phased-array MRi of canine prostate using endorectal and endourethral coils. Magnetic Resonance in Medicine 49(4): 710-715

Martin, R.E.; Ellenbogen, K.A.; Lau, Y.R.; Hall, J.A.; Kay, G.Neal.; Shepard, R.K.; Nixon, J.V.; Wood, M.A. 2002: Phased-array intracardiac echocardiography during pulmonary vein isolation and linear ablation for atrial fibrillation. Journal of Cardiovascular Electrophysiology 13(9): 873-879

Morton, J.B.; Sanders, P.; Davidson, N.C.; Sparks, P.B.; Vohra, J.K.; Kalman, J.M. 2003: Phased-array intracardiac echocardiography for defining cavotricuspid isthmus anatomy during radiofrequency ablation of typical atrial flutter. Journal of Cardiovascular Electrophysiology 14(6): 591-597

Marrouche, N.F.; Martin, D.O.; Wazni, O.; Gillinov, A.Marc.; Klein, A.; Bhargava, M.; Saad, E.; Bash, D.; Yamada, H.; Jaber, W.; Schweikert, R.; Tchou, P.; Abdul-Karim, A.; Saliba, W.; Natale, A. 2003: Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: Impact on outcome and complications. Circulation 107(21): 2710-2716

Morton, J.B.; Sanders, P.; Byrne, M.J.; Power, J.; Mow, C.; Edwards, G.A.; Kalman, J.M. 2001: Phased-array intracardiac echocardiography to guide radiofrequency ablation in the left atrium and at the pulmonary vein ostium. Journal of Cardiovascular Electrophysiology 12(3): 343-348

Venkatachalam, M.; Sathe, S.K. 2003: Phaseolin in vitro pepsin digestibility: role of acids and phenolic compounds. Journal of Agricultural and Food Chemistry 51(11): 3466-3472

Suzuki, O.; Nozawa, Y.; Kawaguchi, T.; Abe, M. 1999: Phaseolus vulgaris leukoagglutinating lectin-binding reactivity in human diffuse large B-cell lymphoma and its relevance to the patient's clinical outcome: Lectin histochemistry and lectin blot analysis. Pathology International 49(10): 874-880

Viala, J.; Vanel, D.; Meingan, P.; Lartigau, E.; Carde, P.; Renschler, M. 1999: Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 212(3): 755-759

Holder, H.; Flay, B.; Howard, J.; Boyd, G.; Voas, R.; Grossman, M. 1999: Phases of alcohol problem prevention research. Alcoholism Clinical and Experimental Research 23(1): 183-194

Pietra, G.; Mortarini, R.; Parmiani, G.; Anichini, A. 2001: Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Research 61(22): 8218-8226

Pepe, M.S.; Etzioni, R.; Feng, Z.; Potter, J.D.; Thompson, M.L.; Thornquist, M.; Winget, M.; Yasui, Y. 2001: Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute 93(14): 1054-1061

Roegiers, F.; Djediat, C.; Dumollard, R.; Rouvière, C.; Sardet, C. 1999: Phases of cytoplasmic and cortical reorganizations of the ascidian zygote between fertilization and first division. Development 126(14): 3101-3117

Bouret, S.; Duvel, A.; Onat, S.; Sara, S.J. 2003: Phasic activation of locus ceruleus neurons by the central nucleus of the amygdala. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 23(8): 3491-3497

Coizet, Véronique.; Comoli, E.; Westby, G.W.Max.; Redgrave, P. 2003: Phasic activation of substantia nigra and the ventral tegmental area by chemical stimulation of the superior colliculus: An electrophysiological investigation in the rat. European Journal of Neuroscience 17(1): 28-40

Oksenberg, A.; Gordon, C.; Arons, E.; Sazbon, L. 2001: Phasic activities of rapid eye movement sleep in vegetative state patients. Sleep 24(6): 703-706

Tandon, R.; Dequardo, J.R.; Taylor, S.F.; Mcgrath, M.; Jibson, M.; Eiser, A.; Goldman, M. 2000: Phasic and enduring negative symptoms in schizophrenia: Biological markers and relationship to outcome. Schizophrenia Research 45(3): 191-201

Takigawa, T.; Alzheimer, C. 2002: Phasic and tonic attenuation of EPSPs by inward rectifier K+ channels in rat hippocampal pyramidal cells. Journal of Physiology 539(Pt 1): 67-75

Dewald, M.; Anthes, N.; Vedder, H.; Voigt, K.; Braun, H.A. 1999: Phasic bursting activity of paraventricular neurons is modulated by temperature and angiotensin II. Journal of Thermal Biology 24(5-6): 339-345

Thakkar, M.M.; Strecker, R.E.; Mccarley, R.W. 2002: Phasic but not tonic REM-selective discharge of periaqueductal gray neurons in freely behaving animals: Relevance to postulates of GABAergic inhibition of monoaminergic neurons. Brain Research 945(2): 276-280

Muhina, Y.G.; Chubarova, A.I.; Neudahin, E.V.; Korneva, T.L.; Kurgasheva, E.K. 2002: Phasic changes of intestinal enzymes activity and state of vegetative nervous system in children with malnutrition and perinatal damage. Pediatriya (Moscow) (3): 30-34

Callamaras, N.; Parker, I. 2000: Phasic characteristic of elementary Ca(2+) release sites underlies quantal responses to IP(3). EMBO Journal 19(14): 3608-3617

Skalidis, E.I.; Kochiadakis, G.E.; Igoumenidis, N.E.; Vardakis, K.E.; Vardas, P.E. 2003: Phasic coronary blood flow velocity pattern and flow reserve in the atrium: Regulation of left atrial myocardial perfusion. Journal of the American College of Cardiology 41(4): 674-680

Schmidt, K.G.; Silverman, N.H.; Rudolph, A.M. 1998: Phasic flow events at the aortic isthmus-ductus arteriosus junction and branch pulmonary artery evaluated by multimodal ultrasonography in fetal lambs. American Journal of Obstetrics and Gynecology 179(5): 1338-1347

Thayer, J.F.; Friedman, B.H.; Borkovec, T.D.; Johnsen, B.H.; Molina, S. 2000: Phasic heart period reactions to cued threat and nonthreat stimuli in generalized anxiety disorder. Psychophysiology 37(3): 361-368

Martin, C.R. 1999: Phasic influences on psychometric measures during the menstrual cycle: Implications for the construct integrity of the locus of control dimension. British Journal of Medical Psychology 72: 217-226

Kiyatkin, E.A.; Kiyatkin, D.E.; Rebec, G.V. 2000: Phasic inhibition of dopamine uptake in nucleus accumbens induced by intravenous cocaine in freely behaving rats. Neuroscience 98(4): 729-741

Del Prato, S.; Marchetti, P.; Bonadonna, R.C. 2002: Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 51(Suppl): S109-S116

Mellen, N.M.; Feldman, J.L. 2000: Phasic lung inflation shortens inspiration and respiratory period in the lung-attached neonate rat brain stem spinal cord. Journal of Neurophysiology 83(5): 3165-3168

Akahoshi, T.; White, D.P.; Edwards, J.K.; Beauregard, J.; Shea, S.A. 2001: Phasic mechanoreceptor stimuli can induce phasic activation of upper airway muscles in humans. Journal of Physiology 531(Pt 3): 677-691

Lewis, G.N.; Byblow, W.D.; Carson, R.G. 2001: Phasic modulation of corticomotor excitability during passive movement of the upper limb: Effects of movement frequency and muscle specificity. Brain Research 900(2): 282-294

Blanqué, R.; Cottereaux, C.; Gardner, C.R. 2001: Phasic production of urinary pyridinium crosslinks in mice: The effect of ovariectomy. Calcified Tissue International 68(2): 102-108

Chapman, C.R.; Oka, S.; Bradshaw, D.H.; Jacobson, R.C.; Donaldson, G.W. 1999: Phasic pupil dilation response to noxious stimulation in normal volunteers: relationship to brain evoked potentials and pain report. Psychophysiology 36(1): 44-52

Rani, S.; Kumar, V. 2000: Phasic response of the photoperiodic clock to wavelength and intensity of light in the redheaded bunting, Emberiza bruniceps. Physiology and Behavior 69(3): 277-283

Fernandez-Galaz, M.C.; Naftolin, F.; Garcia-Segura, L.M. 1999: Phasic synaptic remodeling of the rat arcuate nucleus during the estrous cycle depends on insulin-like growth factor-I receptor activation. Journal of Neuroscience Research 55(3): 286-292

Newell, J.C.; Blue, R.S.; Isaacson, D.; Saulnier, G.J.; Ross, A.S. 2002: Phasic three-dimensional impedance imaging of cardiac activity. Physiological Measurement 23(1): 203-209

Yamamoto, F.; Nishino, T. 2002: Phasic vagal influence on the rate and timing of reflex swallowing. American Journal of Respiratory and Critical Care Medicine 165(10): 1400-1403

Mellen, N.M.; Feldman, J.L. 2001: Phasic vagal sensory feedback transforms respiratory neuron activity in vitro. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 21(18): 7363-7371

Tales, A.; Muir, J.L.; Bayer, A.; Jones, R.; Snowden, R.J. 2002: Phasic visual alertness in Alzheimer's disease and ageing. Neuroreport 13(18): 2557-2560

Banumathi, S.; Dauter, M.; Dauter, Z. 2003: Phasing at high resolution using Ta6Br12 cluster. Acta Crystallographica. Section D Biological Crystallography 59(Pt 3): 492-498

Hao, Q. 2001: Phasing from an envelope. Acta Crystallographica. Section D Biological Crystallography 57(Pt 10): 1410-1414

Volodin, A.A.; Smirnova, E.A.; Bocharova, T.N.; Camerini-Otero, R.Daniel. 2003: Phasing of RecA monomers on quasi-random DNA sequences. FEBS Letters 546(2-3): 203-208

Heuer, H.; Schulna, R. 2002: Phasing of muscle activity during rapid finger oscillations. Journal of Motor Behavior 34(3): 277-289

Ramagopal, U.A.; Dauter, M.; Dauter, Z. 2003: Phasing on anomalous signal of sulfurs: What is the limit?. Acta Crystallographica. Section D Biological Crystallography 59(Pt 6): 1020-1027

Retailleau, P.; Prangé, T. 2003: Phasing power at the K absorption edge of organic arsenic. Acta Crystallographica. Section D Biological Crystallography 59(Pt 5): 887-896

Di Costanzo, L.; Forneris, F.; Geremia, S.; Randaccio, L. 2003: Phasing protein structures using the group-subgroup relation. Acta Crystallographica. Section D Biological Crystallography 59(Pt 8): 1435-1439

Gorokhov, A.V. 2000: Phasmomimidae: Are they Orthoptera or Phasmatoptera?. Paleontologiceskij Zurnal (3): 67-72

Buzás, Z.; Kolosova, I.; Chrambach, A. 1999: PhastSystem electrophoresis in beta-octylglucoside containing gels with immunodetection of a nondenatured vesicle-associated membrane protein. Electrophoresis 20(7): 1390-1397

Yener, G.G.; Guiochon-Mantel, A.; Obuz, F.; Baklan, B.; Oztürk, V.; Kovanlikaya, I.; Cakmur, R.; Genç, A. 2001: Phe 84 deletion of the PMP22 gene associated with hereditary motor and sensory neuropathy HMSN III with multiple cranial neuropathy: Clinical, neurophysiological and magnetic resonance imaging findings. Journal of Neurology 248(3): 193-196

Diederichsen, U.; Biro, C.M. 2000: Phe and Asn side chains in DNA double strands. Bioorganic and Medicinal Chemistry Letters 10(13): 1417-1420

Dalpiaz, A.; Ferretti, M.E.; Pecoraro, R.; Fabbri, E.; Traniello, S.; Scatturin, A.; Spisani, S. 1999: Phe-D-Leu-Phe-D-Leu-Phe derivatives as formylpeptide receptor antagonists in human neutrophils: Cellular and conformational aspects. Biochimica et Biophysica Acta 1432(1): 27-39

Kastin, A.J.; Akerstrom, V.; Hackler, L.; Zadina, J.E. 2000: Phe(13),Tyr(19)-melanin-concentration hormone and the blood-brain barrier: role of protein binding. Journal of Neurochemistry 74(1): 385-391

Eppink, M.H.; Bunthol, C.; Schreuder, H.A.; van Berkel, W.J. 1999: Phe161 and Arg166 variants of p-hydroxybenzoate hydroxylase. Implications for NADPH recognition and structural stability. FEBS Letters 443(3): 251-255

Geha, R.M.; Chen, K.; Shih, J.C. 2000: Phe(208) and Ile(199) in human monoamine oxidase A and B do not determine substrate and inhibitor specificities as in rat. Journal of Neurochemistry 75(3): 1304-1309

Kelley De Zutter, J.; Forget, A.L.; Logan, K.M.; Knight, K.L. 2001: Phe217 regulates the transfer of allosteric information across the subunit interface of the RecA protein filament. Structure 9(1): 47-55

Chen, S.; Lin, F.; Xu, M.; Graham, R.M. 2002: Phe(303) in TMVi of the alpha(1B)-adrenergic receptor is a key residue coupling TM helical movements to G-protein activation. Biochemistry 41(2): 588-596

Chen, S.; Xu, M.; Lin, F.; Lee, D.; Riek, P.; Graham, R.M. 1999: Phe310 in transmembrane VI of the alpha1B-adrenergic receptor is a key switch residue involved in activation and catecholamine ring aromatic bonding. Journal of Biological Chemistry 274(23): 16320-16330

Kubala, M.; Hofbauerová, K.; Ettrich, R.üd.; Kopecký, V.ír.; Krumscheid, R.; Plásek, J.ír.; Teisinger, J.; Schoner, W.; Amler, E. 2002: Phe(475) and Glu(446) but not Ser(445) participate in ATP-binding to the alpha-subunit of Na(+)/K(+)-ATPase. Biochemical and Biophysical Research Communications 297(1): 154-159

Datta, A. 2000: Pheasant abundance in selectively logged and unlogged forests of western Arunachal Pradesh, northeast India. Journal of the Bombay Natural History Society ust; 97(2): 177-183

Rodriguez-Stanley, S.; Robinson, M.; Biscopink, R.J.; Miner, P.B. 2000: Pheasant-induced dysphagia. Digestive Diseases and Sciences 45(9): 1743-1746

Borisovskaya, G.M.; Romanova, M.A.; Shalisko, V.Y. 2001: Phegopteris connectilis (Thelypteridaceae) shoot morphology and stele development. Botanicheskii Zhurnal (Stsburg). 86(8): 62-72

Rizzo, D.M.; Gieser, P.T.; Burdsall, H.H. 2003: Phellinus coronadensis: a new species from southern Arizona, USA. Mycologia 95(1): 74-79

Hattori, T. 1999: Phellinus setifer sp. nov. and P. acontextus, two noteworthy polypores from temperate areas of Japan, with notes on their allies. Mycoscience 40(6): 483-490

Urcelay, C.; Robledo, G.; Rajchenberg, M. 2000: Phellinus tabaquilio sp. nov from Cordoba mountains, central Argentina. Mycotaxon 76: 287-291

Cui, Z.F.; He, P.; Luo, M.; Xia, S.Q.; Wu, M.C. 2002: Phenacetin O-deethylation in extrahepatic tissues of rats. European Journal of Drug Metabolism and Pharmacokinetics 27(2): 107-111

Kudo, S.; Umehara, K.; Hosokawa, M.; Miyamoto, G.; Chiba, K.; Satoh, T. 2000: Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation. Journal of Pharmacology and Experimental Therapeutics 294(1): 80-88

Abbott, F.V.; Hellemans, K.G. 2000: Phenacetin, acetaminophen and dipyrone: Analgesic and rewarding effects. Behavioural Brain Research 112(1-2): 177-186

Taguchi, K.; Kumagai, Y.; Endo, A.; Kikushima, M.; Ishii, Y.; Shimojo, N. 2001: Phenanthraquinone affects endothelial nitric oxide synthase activity through modification of the thiol group: An alternative inhibition mechanism. Journal of Health Science 47(6): 571-574

Fan, C-Wei.; Reinfelder, J.R. 2003: Phenanthrene accumulation kinetics in marine diatoms. Environmental Science and Technology 37(15): 3405-3412

Leong, Y.; Harrison, L.; Powell, A. 1999: Phenanthrene and other aromatic constituents of Bulbophyllum vaginatum. Phytochemistry 50(7): 1237-1241

Muñoz, R.; Guieysse, B.; Mattiasson, B. 2003: Phenanthrene biodegradation by an algal-bacterial consortium in two-phase partitioning bioreactors. Applied Microbiology and Biotechnology 61(3): 261-267

Majumder, P.L.; Sen, S.; Majumder, S. 2001: Phenanthrene derivatives from the orchid Coelogyne cristata. Phytochemistry 58(4): 581-586

Liu, A.; Ahn, I.S.; Mansfield, C.; Lion, L.W.; Shuler, M.L.; Ghiorse, W.C. 2001: Phenanthrene desorption from soil in the presence of bacterial extracellular polymer: observations and model predictions of dynamic behavior. Water Research 35(3): 835-843

Grigg, R.; Savic, V.; Tambyrajah, V. 2000: Phenanthrene type heterocycles via Rh(I) catalysed (2+2+2)-cycloaddition and Pd(0) catalysed arylation. Tetrahedron Letters 41(16): 3003-3006

Kraus, G.A.; Melekhov, A.; Carpenter, S.; Wannemuhler, Y.; Petrich, J. 2000: Phenanthrenequinone antiretroviral agents. Bioorganic and Medicinal Chemistry Letters 10(1): 9-11

Nykamp, J.A.; Bols, N.C.; Carlson, J.C. 2001: Phenanthrenequinone disrupts progesterone production in rat luteal cells. Reproductive Toxicology 15(4): 393-398

Honda, C.; Yamaki, M. 2000: Phenanthrenes from Dendrobium plicatile. Phytochemistry 53(8): 987-990

Piantanida, I.; Palm, B.S.; Cudic, P.; Zinic, M.; Schneider, H.J. 2001: Phenanthridinium cyclobisintercalands. Fluorescence sensing of AMP and selective binding to single-stranded nucleic acids. Tetrahedron Letters 42(38): 6779-6783, 17 September

Muth, G.W.; Hill, W.E. 2001: Phenanthroline-Cu(II) cleavage as a probe of rRNA structure. Methods 23(3): 218-232

Duszyk, M.; Macvinish, L.; Cuthbert, A.W. 2001: Phenanthrolines: A new class of CFTR chloride channel openers. British Journal of Pharmacology 134(4): 853-864

Kim, Kyoung Ja 2000: Phenazine 1-carboxylic acid resistance in phenazine 1-carboxylic acid producing Bacillus sp. B-6. Journal of Biochemistry and Molecular Biology 33(4): 332-336

Denning, G.M.; Iyer, S.S.; Reszka, K.J.; O'Malley, Y.; Rasmussen, G.T.; Britigan, B.E. 2003: Phenazine-1-carboxylic acid, a secondary metabolite of Pseudomonas aeruginosa, alters expression of immunomodulatory proteins by human airway epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 285(3): L584-L592

Wiela-Hojenska, A.; Orzechowska-Juzwenko, K.; Usnarska-Zubkiewicz, L.; Kotlarek-Haus, S.; Hurkacz, M. 1999: Phenazone as a marker of liver-metabolic function in patients with acute leukemia. International Journal of Clinical Pharmacology and Therapeutics 37(5): 234-237

Verleye, M.; Heulard, I.; Gillardin, J.M. 2000: Phenazone potentiates the local anaesthetic effect of lidocaine in mice. Pharmacological Research 41(5): 539-542

Linn, G.S.; Javitt, D.C. 2001: Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. Neuroreport 12(1): 117-120

Noda, A.; Noda, Y.; Kamei, H.; Ichihara, K.; Mamiya, T.; Nagai, T.; Sugiura, S.; Furukawa, H.; Nabeshima, T. 2001: Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 24(4): 451-460

Crosby, M.J.; Hanson, J.E.; Fleckenstein, A.E.; Hanson, G.R. 2002: Phencyclidine increases vesicular dopamine uptake. European Journal of Pharmacology 438(1-2): 75-78

Griffiths, M.R.; Mitchell, I.J.; Cooper, A.J. 1999: Phencyclidine induces D-1 dopamine receptor mediated Fos-like immunoreactivity in discretely localised populations of striatopallidal and striatoentopeduncular neurons in the rat. Brain Research 821(1): 177-189

Moy, S.S.; Breese, G.R. 2002: Phencyclidine supersensitivity in rats with neonatal dopamine loss. Psychopharmacology 161(3): 255-262

Bowen, S.E.; Wiley, J.L.; Jones, H.E.; Balster, R.L. 1999: Phencyclidine- and diazepam-like discriminative stimulus effects of inhalants in mice. Experimental and Clinical Psychopharmacology 7(1): 28-37

Mori, A.; Noda, Y.; Mamiya, T.; Miyamoto, Y.; Nakajima, A.; Furukawa, H.; Nabeshima, T. 2001: Phencyclidine-induced discriminative stimulus is mediated via phencyclidine binding sites on the N-methyl-D-aspartate receptor-ion channel complex, not via sigma(1) receptors. Behavioural Brain Research 119(1): 33-40

Balla, A.; Hashim, A.; Burch, S.; Javitt, D.C.; Lajtha, A.; Sershen, H. 2001: Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. Neurochemical Research 26(8-9): 1001-1006

Gold, D.G.; Fatemi, S.H.ssein 2003: Phenelzine-opiate-induced delirium complicated by phenelzine withdrawal. Journal of Pharmacy Technology 19(1): 19-22

Vidyakin, A.I. 2001: Phenes of wood plants: Identification, scaling, and the use in population studies as exemplified by Pinus sylvestris L. Ekologiya (Moscow) (3): 197-202

Ono, M.; Yoshida, A.; Ito, Y.; Nohara, T. 1999: Phenethyl alcohol glycosides and isopentenol glycoside from fruit of Bupleurum falcatum. Phytochemistry 51(6): 819-823

Colarusso, S.; Koch, U.; Gerlach, B.; Steinkühler, C.; De Francesco, R.; Altamura, S.; Matassa, V.G.; Narjes, F. 2003: Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling. Journal of Medicinal Chemistry 46(3): 345-348

Xiao, D.; Singh, S.V. 2002: Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Research 62(13): 3615-3619

Gengler-Nowak, Karla 2002: Phenetic analyses of morphological traits in the Malesherbia humilis complex (Malesherbiaceae). Taxon 51(2): 281-293

Cavazos, M.L.; Jiao MeiJun; Bye, R. 2000: Phenetic analysis of Datura section Dutra (Solanaceae) in Mexico. Botanical Journal of the Linnean Society 133(4): 493-507

Romero, A.; Luna, M.; Garcia, E.; Passini, M.F. 2000: Phenetic analysis of the Mexican midland pinyon pines, Pinus cembroides and Pinus johannis. Botanical Journal of the Linnean Society 133(2): 181-194

Baeza, P.-Carlos, M. 1998: Phenetic and principal components analysis in the South American species of Rytidosperma Steud. (Poaceae). Gayana Botanica 55(1): 11-15

Goulao, L.; Monte Corvo, L.; Oliveira, C.M. 2001: Phenetic characterization of plum cultivars by high multiplex ratio markers: Amplified fragment length polymorphisms and inter-simple sequence repeats. Journal of the American Society for Horticultural Science 126(1): 72-77

Ioannidou, S.; Foustoukou, M. 1998: Phenetic criteria for identification of Streptococci viridans in the routine laboratory of clinical microbiology. Deltion Ellenikes Mikrobiologikes Etaireias 43(5): 475-481

Vegetti, Abelardo-Carlos 1998: Phenetic study of inflorescences of Andropogoneae (Poaceae). Kurtziana 26: 145-163

Peskov, V.N.; Emelyanov, I.G. 2000: Phenetical analysis of water vole (Arvicola terrestris) population structure in central and eastern Palaearctics. Vestnik Zoologii 34(6): 65-70

Lee, J.; Chan, S.L.; Lu, C.; Lane, M.A.; Mattson, M.P. 2002: Phenformin suppresses calcium responses to glutamate and protects hippocampal neurons against excitotoxicity. Experimental Neurology 175(1): 161-167

Wie, M.B.; Cho, Y.J.; Jhoo, W.K.; Kim, H.C. 1999: Phenidone attenuates oxygen/glucose deprivation-induced neurotoxicity by antioxidant and antiapoptotic action in mouse cortical cultures. Neuroscience Letters 272(2): 91-94

Kim, H.C.; Jhoo, W.K.; Bing, G.; Shin, E.J.; Wie, M.B.; Kim, W.K.; Ko, K.H. 2000: Phenidone prevents kainate-induced neurotoxicity via antioxidant mechanisms. Brain Research 874(1): 15-23

Tepluk, N.M.; Lebedeva, L.M.; Kolomietz, L.I.; Butkiewicz, D.M.; Chorazy, M.R.; Poirier, M.C.; Obolenskaya, M.Y. 2001: Pheno- and genotyping of placental detoxifying system in ecologically unfavorable regions of Ukraine. Ukrainskii Biokhimicheskii Zhurnal 73(3): 126-134

Montañez, S.; Kline, A.E.; Gasser, T.A.; Hernandez, T.D. 2000: Phenobarbital administration directed against kindled seizures delays functional recovery following brain insult. Brain Research 860(1-2): 29-40

Patel, N.J.; Zamek-Gliszczynski, M.J.; Zhang, P.; Han, Y.-H.; Jansen, P.L.M.; Meier, P.J.; Stieger, B.; Brouwer, K.L.R. 2003: Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Molecular Pharmacology 64(1): 154-159

Rana, S.V.S.; Gupta, S. 1999: Phenobarbital alters liver and kidney function in toluene- and trichloroethylene-treated rats. Toxic Substance Mechanisms 18(1): 3-10

Prasad, A.; Williamson, J.M.; Bertram, E.H. 2002: Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus. Annals of Neurology 51(2): 175-181

Bowyer, J.F.; Holson, R.R.; Miller, D.B.; O'callaghan, J.P. 2001: Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation. Brain Research 919(1): 179-183

Kinoshita, A.; Wanibuchi, H.; Morimura, K.; Wei, M.; Shen, J.; Imaoka, S.; Funae, Y.; Fukushima, S. 2003: Phenobarbital at low dose exerts hormesis in rat hepatocarcinogenesis by reducing oxidative DNA damage, altering cell proliferation, apoptosis and gene expression. Carcinogenesis 24(8): 1389-1399

Mesquita, M.Beranos.Soares.; Moraes-Santos, T.; Moraes, Márcio.Flávio.Dutra. 2002: Phenobarbital blocks the lung edema induced by centrally injected tityustoxin in adult Wistar rats. Neuroscience Letters 332(2): 119-122

Taliansky, A.; Kramer, U.; Neufeld, M.Y. 2000: Phenobarbital coma for psychogenic status epilepticus. Harefuah 138(4): 294-6 342

Painter, M.J.; Scher, M.S.; Stein, A.D.; Armatti, S.; Wang, Z.; Gardiner, J.C.; Paneth, N.; Minnigh, B.; Alvin, J. 1999: Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine 341(7): 485-489

Elliott, E.S.; Buck, M.L. 1999: Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. Annals of PharmacoTherapy 33(4): 419-422

Yazar, E.; Demir, O.; Elmas, M.; Bas, A.L.; Tras, B. 2002: Phenobarbital effects on brain and liver tissues enzyme activity in Balb/C mice. Acta Veterinaria Brno 71(3): 309-312

Hashimoto, M.; Kothary, P.C.; Raper, S.E. 1999: Phenobarbital in comparison with carbon tetrachloride and phenobarbital-induced cirrhosis in rat liver regeneration. Journal of Surgical Research 81(2): 164-169

El Adlouni, C.; Pinelli, E.; Azémar, B.; Zaoui, D.; Beaune, P.; Pfohl-Leszkowicz, A. 2000: Phenobarbital increases DNA adduct and metabolites formed by ochratoxin A: role of CYP 2C9 and microsomal glutathione-S-transferase. Environmental and Molecular Mutagenesis 35(2): 123-131

Pappas, P.; Stephanou, P.; Karamanakos, P.; Vasiliou, V.; Marselos, M. 2001: Phenobarbital inducibility and differences in protein expression of an animal model. Chemico-Biological Interactions 130-132(1-3): 275-283

Ganem, L.G.; Trottier, E.; Anderson, A.; Jefcoate, C.R. 1999: Phenobarbital induction of CYP2B1/2 in primary hepatocytes: endocrine regulation and evidence for a single pathway for multiple inducers. Toxicology and Applied Pharmacology 155(1): 32-42

Marc, N.; Fautrel, A.; Damon, M.; Guillouzo, A.; Corcos, L. 2000: Phenobarbital induction of aldehyde dehydrogenase type 2 mRNA in mouse liver: a candidate region on chromosome 7 for a putative regulatory gene. Biochemical Genetics 38(9-10): 297-307

Kakizaki, S.; Yamamoto, Y.; Ueda, A.; Moore, R.; Sueyoshi, T.; Negishi, M. 2003: Phenobarbital induction of drug/steroid-metabolizing enzymes and nuclear receptor CAR. Biochimica et Biophysica Acta 1619(3): 239-242

Brown Croyts, L.M.; Caton, P.W.; Radecki, D.T.; Mcpherson, S.L. 2000: Phenobarbital pre-treatment prevents kainic acid-induced impairments in acquisition learning. Life Sciences 67(6): 643-650

Sanders, S.; Thorgeirsson, S.S. 1999: Phenobarbital promotes liver growth in c-myc/TGF-alpha transgenic mice by inducing hypertrophy and inhibiting apoptosis. Carcinogenesis 20(1): 41-49

Ramsden, R.; Beck, N.B.; Sommer, K.M.; Omiecinski, C.J. 1999: Phenobarbital responsiveness conferred by the 5'-flanking region of the rat CYP2B2 gene in transgenic mice. Gene 228(1-2): 169-179

Castelao, J.E.; Gago-Dominguez, M.; Yuan, J.M.; Ross, R.K.; Yu, M.C. 2003: Phenobarbital use and bladder cancer risk. European Journal of Epidemiology 18(7): 659-664

Viollon-Abadie, C.; Lassere, D.; Debruyne, E.; Nicod, L.; Carmichael, N.; Richert, L. 1999: Phenobarbital, beta-naphthoflavone, clofibrate, and pregnenolone-16alpha-carbonitrile do not affect hepatic thyroid hormone UDP-glucuronosyl transferase activity, and thyroid gland function in mice. Toxicology and Applied Pharmacology 155(1): 1-12

Deutsch, W.A.; Kukreja, A.; Shane, B.; Hegde, V. 2001: Phenobarbital, oxazepam and Wyeth 14,643 cause DNA damage as measured by the Comet assay. Mutagenesis 16(5): 439-442

Zelko, I.; Negishi, M. 2000: Phenobarbital-elicited activation of nuclear receptor CAR in induction of cytochrome P450 genes. Biochemical and Biophysical Research Communications 277(1): 1-6

Agrawal, A.K.; Shapiro, B.H. 2003: Phenobarbital-imprinted overinduction of adult constituent CYP isoforms. Pharmacology 68(4): 204-215

Matsuki, Y.; Yamada, H.; Oguri, K. 1998: Phenobarbital-mediated induction of the CYP2B subfamily is not antagonized by picrotoxin, a potent antagonist of barbiturates in the central nervous system. Biological and Pharmaceutical Bulletin 21(11): 1160-1162

Kawamoto, T.; Sueyoshi, T.; Zelko, I.; Moore, R.; Washburn, K.; Negishi, M. 1999: Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Molecular and Cellular Biology 19(9): 6318-6322

Gould, S.; Sidaway, J.; Sansom, N.; Betton, G.; Orton, T. 2001: Phenobarbitone-induced liver response in wild type and in p53 deficient mice. Toxicology Letters 122(2): 131-140

Sinha, S.; Kamath, V.; Arunodaya, G.R.; Taly, A.B. 2002: Phenobarbitone induced gingival hyperplasia. Journal of Neurology Neurosurgery and Psychiatry 73(5): 601

Boylan, G.B.; Rennie, J.M.; Pressler, R.M.; Wilson, G.; Morton, M.; Binnie, C.D. 2002: Phenobarbitone, neonatal seizures, and video-EEG. Archives of Disease in Childhood. Fetal and Neonatal Edition 86(3): F165-F170

Martin, N.C.; Mcgregor, A.H.; Sansom, N.; Gould, S.; Harrison, D.J. 2001: Phenobarbitone-induced ploidy changes in liver occur independently of p53. Toxicology Letters 119(2): 109-115

Samudre, K.R.; Mani, S.A.; Vathsala, P.G.; Rangarajan, P.N.; Padmanaban, G. 2002: Phenobarbitone-mediated translocation of the cytosolic proteins interacting with the 5'-proximal region of rat liver CYP2B1/B2 gene into the nucleus. Biochemical and Biophysical Research Communications 292(2): 312-317

Tomoda, H.; Namatame, I.; Si, S.; Kawaguchi, K.; Masuma, R.; Namikoshi, M.; Omura, S. 1999: Phenochalasins, inhibitors of lipid droplet formation in mouse macrophages, produced by Phomopsis sp. FT-0211. Journal of Antibiotics 52(10): 851-856

Kopp, P.; Arseven, O.K.; Sabacan, L.; Kotlar, T.; Dupuis, J.; Cavaliere, H.; Santos, C.L.; Jameson, J.L.; Medeiros-Neto, G. 1999: Phenocopies for deafness and goiter development in a large inbred Brazilian kindred with Pendred's syndrome associated with a novel mutation in the PDS gene. Journal of Clinical Endocrinology and Metabolism 84(1): 336-341

Grimes, D.A.; Barclay, C.L.; Duff, J.; Furukawa, Y.; Lang, A.E. 2002: Phenocopies in a large GCH1 mutation positive family with dopa responsive dystonia: confusing the picture?. Journal of Neurology Neurosurgery and Psychiatry 72(6): 801-804

Minin, A.A.; Gutnikov, V.A. 2000: Phenoindication of current fluctuations in climate in the European part of Russia by the example of some forest-forming species and birds. Lesovedenie 2: 68-71

Ishii, W.; Matsuda, M.; Nakamura, N.; Katsumata, S.; Toriumi, H.; Suzuki, A.; Ikeda, S-ichi. 2003: Phenol Congo red staining enhances the diagnostic value of abdominal fat aspiration biopsy in reactive AA amyloidosis secondary to rheumatoid arthritis. Internal Medicine 42(5): 400-405

Alva, V.A.; Peyton, B.M. 2003: Phenol and catechol biodegradation by the haloalkaliphile Halomonas campisalis: Influence of pH and salinity. Environmental Science and Technology 37(19): 4397-4402

Lin, S.H.; Cheng, M.J. 2000: Phenol and chlorophenol removal from aqueous solution by organobentonites. Environmental Technology 21(4): 475-482

Kortenska, V.D.; Yanishlieva, N.V.; Kasaikina, O.T.; Totzeva, I.R.; Boneva, M.I.; Russina, I.F. 2002: Phenol antioxidant efficiency in various lipid substrates containing hydroxy compounds. European Journal of Lipid Science and Technology 104(8): 513-519

Beshay, U.A.d-El-Haleem, D.M.awad, H.Z.ki, S. 2002: Phenol biodegradation by free and immobilized Acinetobacter. Biotechnology letters 24(15): 1295-1297

Chernyaeva, G.N.; Peryshkina, G.I. 1998: Phenol compounds of the bark of Abies sibirica Ledeb. Rastitel'nye Resursy 34(2): 51-55

Léonard, D.; Youssef, C.B.; Destruhaut, C.; Lindley, N.D.; Queinnec, I. 1999: Phenol degradation by Ralstonia eutropha: Colorimetric determination of 2-hydroxymuconate semialdehyde accumulation to control feed strategy in fed-batch fermentations. Biotechnology and Bioengineering 65(4): 407-415

Santos, V.L.; Heilbuth, N.ád.M.; Braga, D.úb.T.; Monteiro, A.S.; Linardi, V.R. 2003: Phenol degradation by a Graphium sp. FIB4 isolated from industrial effluents. Journal of Basic Microbiology 43(3): 238-248

Heesche-Wagner, K.; Schwarz, T.; Kaufmann, M. 1999: Phenol degradation by an enterobacterium: A Klebsiella strain carries a TOL-like plasmid and a gene encoding a novel phenol hydroxylase. Canadian Journal of Microbiology 45(2): 162-171

Bolaños, R.M.; Varesche, M.B.; Zaiat, M.; Foresti, E. 2001: Phenol degradation in horizontal-flow anaerobic immobilized biomass (HAIB) reactor under mesophilic conditions. Water Science and Technology: a Journal of the International Association on Water Pollution Research 44(4): 167-174

Israni, S.H.; Koli, S.S.; Patwardhan, A.W.; Melo, J.S.; D'souza, S.F. 2002: Phenol degradation in rotating biological contactors. Journal of Chemical Technology and Biotechnology 77(9): 1050-1057

Alexieva, Z.; Gerginova, M.; Shivarova, N.; Atanasov, B.; Zlateva, P. 2003: Phenol degradation kinetics of Trichosporon cutaneum mutant strains. Dokladi na B"lgarskata Akademiya na Naukite 56(4): 101-104

Haeseler, G.; Piepenbrink, A.; Bufler, J.; Dengler, R.; Hecker, H.; Aronson, J.; Piepenbrock, S.; Leuwer, M. 2001: Phenol derivatives accelerate inactivation kinetics in one inactivation-deficient mutant human skeletal muscle Na(+) channel. European Journal of Pharmacology 416(1-2): 11-18

Dimitrieva, G.Y.; Khristoforova, N.K.; Drozdovskaya, O.A.; Tyuveleva, E.E.; Dimitriev, S.M.; Shevchenko, L.S. 1999: Phenol detoxication by microorganisms of the sea coastal zone. Mikrobiologiya 68(1): 107-113

Griva, E.; Pessione, E.; Divari, S.; Valetti, F.; Cavaletto, M.; Rossi, G.Luigi.; Giunta, C. 2003: Phenol hydroxylase from Acinetobacter radioresistens S13. Isolation and characterization of the regulatory component. European Journal of Biochemistry 270(7): 1434-1440

Solyanikova; Golovleva 1999: Phenol hydroxylases: An update. Biochemistry. Biokhimiia 64(4): 365-372

Ren, S. 2003: Phenol mechanism of toxic action classification and prediction: A decision tree approach. Toxicology Letters 144(3): 313-323

Williams, C.J.; Shingara, E.A.; Yavitt, J.B. 2000: Phenol oxidase activity in peatlands in New York State: Response to summer drought and peat type. Wetlands 20(2): 416-421

Vione, D.; Maurino, V.; Minero, C.; Pelizzetti, E. 2002: Phenol photonitration. Annali di Chimica 92(9): 919-929

Vione, D.; Maurino, V.; Minero, C.; Pelizzetti, E. 2001: Phenol photonitration upon UV irradiation of nitrite in aqueous solution I: Effects of oxygen and 2-propanol. Chemosphere 45(6-7): 893-902

Vione, D.; Maurino, V.; Minero, C.; Pelizzetti, E. 2001: Phenol photonitration upon UV irradiation of nitrite in aqueous solution II: Effects of pH and TiO2. Chemosphere 45(6-7): 903-910

Mary, P.L.; Rao, J.Prakasa. 2002: Phenol red inhibits uptake of phosphate by the everted gut sacs of mice. Kobe Journal of Medical Sciences 48(1-2): 59-62

Błaszczyk, M.ła.; Son, T.T.T.; Przytocka-Jusiak, M.; Suszek, A. 2002: Phenol removal in packed bed reactor under denitrifying conditions. Acta Microbiologica Polonica 51(1): 39-45

Honma, W.; Shimada, M.; Sasano, H.; Ozawa, S.; Miyata, M.; Nagata, K.; Ikeda, T.; Yamazoe, Y. 2002: Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metabolism and Disposition: the Biological Fate of Chemicals 30(8): 944-949

Steiner, M.; Bastian, M.; Schulz, W.A.; Pulte, T.; Franke, K.H.; Röhring, A.; Wolff, J.M.; Seiter, H.; Schuff-Werner, P. 2000: Phenol sulphotransferase SULT1A1 polymorphism in prostate cancer: Lack of association. Archives of Toxicology 74(4-5): 222-225

Bamber, D.E.; Fryer, A.A.; Strange, R.C.; Elder, J.B.; Deakin, M.; Rajagopal, R.; Fawole, A.; Gilissen, R.A.; Campbell, F.C.; Coughtrie, M.W. 2001: Phenol sulphotransferase SULT1A1*1 genotype is associated with reduced risk of colorectal cancer. Pharmacogenetics 11(8): 679-685

Pedersen, G.; Brynskov, J.; Saermark, T. 2002: Phenol toxicity and conjugation in human colonic epithelial cells. Scandinavian Journal of Gastroenterology 37(1): 74-79

Boszczyk-Maleszak, H.; Chorazy, M.; Bieszkiewicz, E.; Kacieszczenko, J. 2002: Phenol utilisation by fungi isolated from activated sludge. Acta Microbiologica Polonica 51(2): 183-191

Plekhanov, S.E. 1998: Phenol-induced accumulation of fatty acids in culture medium of algae Scenedesmus quadricauda. Izvestiya Akademii Nauk Seriya Biologicheskaya (Moscow) (2): 277-282

Robles; Lucas; de Cienfuegos GA; Gálvez 2000: Phenol-oxidase (laccase) activity in strains of the hyphomycete Chalara paradoxa isolated from olive mill wastewater disposal ponds. Enzyme and Microbial Technology 26(7): 484-490

Duffner, F.M.; Kirchner, U.; Bauer, M.P.; Müller, R. 2000: Phenol/cresol degradation by the thermophilic Bacillus thermoglucosidasius A7: Cloning and sequence analysis of five genes involved in the pathway. Gene 256(1-2): 215-221

Ruther, J.; Reinecke, A.; Tolasch, T.; Hilker, M. 2002: Phenol--another cockchafer attractant shared by Melolontha hippocastani Fabr. and M. melolontha L. Zeitschrift für Naturforschung. C Journal of Biosciences 57(9-10): 910-913

Chernyaeva, G.N.; Permyakova, G.V. 2000: Phenolcarbonic acids and monomer flavanes of Larix sibirica Ledeb. bark. Rastitel'nye Resursy 36(3): 47-51

Ley, J.P. 2001: Phenolic acid amides of phenolic benzylamines against UVA-induced oxidative stress in skin. International Journal of Cosmetic Science 23(1): 35-48

Silva, F.A.; Borges, F.; Guimarães, C.; Lima, J.L.; Matos, C.; Reis, S. 2000: Phenolic acids and derivatives: studies on the relationship among structure, radical scavenging activity, and physicochemical parameters. Journal of Agricultural and Food Chemistry 48(6): 2122-2126

Tu-Pengfei; Wu-Weizhong; Zheng-Junhua 1999: Phenolic acids from the bulbs of Notholirion bulbuliferum. Yaoxue Xuebao 34(1): 39-42

Weidner, S.; Amarowicz, R.; Karamac, M.; Dabrowski, G. 1999: Phenolic acids in caryopses of two cultivars of wheat, rye and triticale that display different resistance to pre-harvest sprouting. European Food Research and Technology 210(2): 109-113

Swiatek, L.; Grabias, B.; Kalemba, D. 1998: Phenolic acids in certain medicinal plants of the genus Artemisia. Pharmaceutical and Pharmacological Letters 8(4): 158-160

Robbins, R.J. 2003: Phenolic acids in foods: an overview of analytical methodology. Journal of Agricultural and Food Chemistry 51(10): 2866-2887

Kowalski, R.; Wiercinski, J. 2003: Phenolic acids in leaves of three Silphium L. species: Short communication. Polish Journal of Food and Nutrition Sciences 12(1): 17-20

Krizková, L.; Nagy, M.; Polónyi, J.; Dobias, J.; Belicová, A.; Grancai, D.; Krajcovic, J. 2000: Phenolic acids inhibit chloroplast mutagenesis in Euglena gracilis. Mutation Research 469(1): 107-114

Morton, L.W.; Croft, K.D.; Puddey, I.B.; Byrne, L. 2000: Phenolic acids protect low density lipoproteins from peroxynitrite-mediated modification in vitro. Redox Report: Communications in Free Radical Research 5(2-3): 124-125

Seneviratne, G.; Jayasinghearachchi, H.S. 2003: Phenolic acids: Possible agents of modifying N2-fixing symbiosis through rhizobial alteration?. Plant and Soil 252(2): 385-395

Yayli, N.; Baltaci, C.; Genc, H.; Terzioglu, S. 2002: Phenolic and flavone C-glycosides from Scleranthus uncinatus. Pharmaceutical Biology 40(5): 369-373

Durmus, N.; Coskuncelebi, K.; Kadioglu, A.; Beyazoglu, O. 2002: Phenolic and sugar compositions of some Hieracium L. (Asteraceae) leaves in North East Anatolia. Bulgarian Journal of Plant Physiology 28(1-2): 30-35

Karagiannis, S.; Economou, A.; Lanaridis, P. 2000: Phenolic and volatile composition of wines made from Vitis vinifera Cv. Muscat lefko grapes from the island of Samos. Journal of Agricultural and Food Chemistry 48(11): 5369-5375

Peterson, D.M.; Emmons, C.L.; Hibbs, A.H. 2001: Phenolic antioxidants and antioxidant activity in pearling fractions of oat groats. Journal of Cereal Science 33(1): 97-103

Parihar, M.S.; Hemnani, T. 2003: Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. Journal of Biosciences 28(1): 121-128

Schroeter, H.; Williams, R.J.; Matin, R.; Iversen, L.; Rice-Evans, C.A. 2000: Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. Free Radical Biology and Medicine 29(12): 1222-1233

Kjallstrand, J.P.tersson, G. 2001: Phenolic antioxidants in alder smoke during industrial meat curing. Food chemistry 74(1): 85-89

Noguchi, N.; Niki, E. 2000: Phenolic antioxidants: A rationale for design and evaluation of novel antioxidant drug for atherosclerosis. Free Radical Biology and Medicine 28(10): 1538-1546

Cheng, Z.; Ren, J.; Li, Y.; Chang, W.; Chen, Z. 2002: Phenolic antioxidants: electrochemical behavior and the mechanistic elements underlying their anodic oxidation reaction. Redox Report: Communications in Free Radical Research 7(6): 395-402

Talcott, S.T.; Howard, L.R. 1999: Phenolic autoxidation is responsible for color degradation in processed carrot puree. Journal of Agricultural and Food Chemistry 47(5): 2109-2115

Basra, R., K.; Basra, A., S. 2001: Phenolic biosynthesis inhibitors accentuate the effects of heat-shock injury in mung bean seedlings: Alleviation by salicylic acid. Journal of New Seeds 3(4): 41-49

Duval, B.; Shetty, K.; Thomas, W., H. 1999: Phenolic compounds and antioxidant properties in the snow alga Chlamydomonas nivalis after exposure to UV light. Journal of Applied Phycology 11(6): 559-566

Fabios, M.; Lopez-Toledano, A.; Mayen, M.; Merida, J.; Medina, M. 2000: Phenolic compounds and browning in sherry wines subjected to oxidative and biological aging. Journal of Agricultural and Food Chemistry 48(6): 2155-2159

Gomez-Plaza, E.; Gil-Munoz, R.; Lopez-Roca, J.M.; Martinez-Cutillas, A.; Fernandez-Fernandez, J.I. 2001: Phenolic compounds and color stability of red wines: Effect of skin maceration time. American Journal of Enology and Viticulture 52(3): 266-270

Hayashi, K.; Ikoma, R.; Deyama, T. 2001: Phenolic compounds and iridoids from Leonurus sibiricus. Natural Medicines 55(5): 276

Pasqualini, V.; Robles, C.; Garzino, S.; Greff, S.; Bousquet-Melou, A.; Bonin, G. 2003: Phenolic compounds content in Pinus halepensis Mill. needles: a bioindicator of air pollution. Chemosphere 52(1): 239-248

Giertych, M., J.; Karolewski, P. 2000: Phenolic compounds distribution along the length of Scots pine needles in a polluted and control environment and its connection with necroses formation. Acta Societatis Botanicorum Poloniae 69(2): 127-130

Sinz, A.M., R.E., F.V.; Santisuk, T.C., S.R., V. 1999: Phenolic compounds from Anomianthus dulcis. Phytochemistry 50(6): 1069-1072

Yue-Jian-Min; Zhao-Qin-Shi; Lin-Zhong-Wen; Sun-Han-Dong 2000: Phenolic compounds from Erigeron breviscapus (Compositae). Acta Botanica Sinica 42(3): 311-315

Abdel-Sattar, E.; Kohiel, M.A.; Shihata, I.A.; el-Askary, H. 2000: Phenolic compounds from Eucalyptus maculata. Die Pharmazie 55(8): 623-624

Nishibe, S.; Kodama, A.; Noguchi, Y.; Han, Y. 2001: Phenolic compounds from seeds of Plantago ovata and P. psyllium. Natural Medicines 55(5): 258-261

Davi, M.L.; Gnudi, F. 1999: Phenolic compounds in surface water. Water Research 33(14): 3213-3219

Caponio, F.; Gomes, T.; Pasqualone, A. 2001: Phenolic compounds in virgin olive oils: Influence of the degree of olive ripeness on organoleptic characteristics and shelf-life. European Food Research and Technology 212(3): 329-333

Katakawa, J.'ichi; Tetsumi, T.; Kamei, S.; IIda, T.; Katai, M. 2000: Phenolic compounds of fruit of Coix lachryma-jobi L. Natural Medicines 54(5): 257-260

Muñoz, O.; Peña, R.C.; Ureta, E.; Montenegro, G.; Caldwell, C.; Timmermann, B.N. 2001: Phenolic compounds of propolis from Central Chilean matorral. Zeitschrift für Naturforschung. C Journal of Biosciences 56(3-4): 273-277

Machida, K.; Ando, M.; Yaoita, Y.; Kakuda, R.; Kikuchi, M. 2001: Phenolic compounds of the leaves of Catalpa ovata G. DON. Natural Medicines 55(2): 64-67

Caponio, F.; Alloggio, V.; Gomes, T. 1999: Phenolic compounds of virgin olive oil: Influence of paste preparation techniques. Food Chemistry 64(2): 203-209

Green, P.W.C.; Stevenson, P.C.; Simmonds, M.S.J.; Sharma, H.C. 2003: Phenolic compounds on the pod-surface of pigeonpea, Cajanus cajan, mediate feeding behavior of Helicoverpa armigera larvae. Journal of Chemical Ecology 29(4): 811-821

De-Beer, D.; Joubert, E.; Gelderblom, W.C.A.; Manley, M. 2002: Phenolic compounds: A review of their possible role as in vivo antioxidants of wine. South African Journal of Enology and Viticulture 23(2): 48-61

Seca, A.M.; Silva, A.M.; Silvestre, A.J.; Cavaleiro, J.A.; Domingues, F.M.; Pascoal-Neto, C. 2001: Phenolic constituents from the core of kenaf (Hibiscus cannabinus). Phytochemistry 56(7): 759-767

Jayaprakasha, G., K.; Rao, L.-Jaganmohan 2000: Phenolic constituents from the lichen Parmotrema stuppeum (Nyl.) hale and their antioxidant activity. Zeitschrift fuer Naturforschung Section C Journal of Biosciences 55(11-12): 1018-1022